Sentinel lymph node biopsy in breast cancer : aspects on indications and limitations by Holmstrand Zetterlund, Linda
  
 
From the Department of Clinical Science and Education, 
Södersjukhuset  
Karolinska Institutet, Stockholm, Sweden 
SENTINEL LYMPH NODE BIOPSY IN 
BREAST CANCER-ASPECTS ON 
INDICATIONS AND LIMITATIONS 
Linda Holmstrand Zetterlund 
 
 
Stockholm 2017 
 
  
  
 
 
 
 
Front page illustration: Reproduced with permission from IntraMedical Imaging LLC. 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-Print AB 2017. 
© Linda Zetterlund, 2017 
ISBN 978-91-7676-576-0 
  
  
Institutionen för klinisk forskning och utbildning 
Sentinel lymph node biopsy in breast cancer 
– Aspects on indications and limitations 
 
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid Karolinska Institutet 
offentligen försvaras i Aulan, Södersjukhuset. 
 
Fredagen den 21 april, kl 09.00 
av 
Linda Holmstrand Zetterlund 
 
Huvudhandledare: 
MD PhD Fuat Celebioglu  
Karolinska Institutet 
Institutionen för klinisk forskning 
och utbildning 
 
Bihandledare: 
Professor Rimma Axelsson 
Karolinska Institutet 
Institutionen för klinisk vetenskap, 
intervention och teknik 
 
Docent Jana de Boniface 
Karolinska Institutet 
Institutionen för molekylär medicin 
 och kirurgi 
  
Professor Jan Frisell 
Karolinska Institutet 
Institutionen för molekylär medicin 
 och kirurgi 
 
 
Stockholm 2017 
Fakultetsopponent: 
Ellen Schlichting, MD, PhD 
Oslo Universitet 
Institutt for klinisk medisin, Medicinsk fakultet 
 
 
Betygsnämnd: 
Docent Signe Borgquist 
Lunds Universitet 
Institutionen för kliniska vetenskaper,  
Avdelningen för onkologi och patologi 
 
 
Docent Jan Zedenius 
Karolinska Institutet 
Institutionen för molekylär medicin 
och kirurgi  
 
Johan Lindholm 
Karolinska Institutet 
Institutionen för onkologi och patologi 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Till Fredrik, Klara och Hugo 
 
  
  
  
ABSTRACT 
__________________________________________________________________________ 
Axillary lymph node status is the most important prognostic factor in breast cancer. Sentinel lymph 
node biopsy (SLNB) was introduced in the late 1990s and has replaced axillary lymph node dissection 
(ALND) as the gold standard axillary nodal staging procedure in early breast cancer due to higher 
accuracy and less morbidity compared with ALND. The overall aim of this thesis was to investigate 
SLNB and its current role in breast cancer today with a focus on current controversies and its 
limitations in different clinical settings. 
The first paper (I) is a national registry study investigating the incidence of positive sentinel lymph 
nodes (SLNs) in women with a postoperative diagnosis of pure DCIS (ductal carcinoma in situ). We 
also investigated whether additional tumor sectioning could reveal occult tumor invasion among the 
patients with tumor deposits in their SLNs. SLNB was performed in 753 patients of whom 11 had 
tumor deposits in their SLNs. Two patients had macro- and three micrometastasis (N1). Six patients 
had isolated tumor cells (N0(i+)), resulting in a SLN positive rate of 0.7% (5/753). We did not find 
any risk factors for SLN metastasis. Occult invasion was found to the same extent among patients 
with SLN metastasis 9% (1/11) as in the matched control group of 10% (2/21). 
The aim of the second paper (II) was to evaluate lymph drainage patterns to the axillary lymph nodes 
with hybrid SPECT/CT imaging before, compared with six weeks after a diagnostic breast excision of 
an unsuspicious breast tumor. SPECT (single photon emission computed tomography) integrates 
nuclear medicine imaging with CT (computed tomography) which results in functional images with 
precise anatomical localization of radioactive SLNs. The contralateral breast served as a control. The 
SLN detection rate was 91.9% (34/37) on operated sides postoperatively compared with 93.7% 
(104/111) on non-operated sides, p=0.0771. Partial or total concordance regarding number and 
localization of radioactive lymph nodes was not significantly lower on operated at 85.7% (30/35) 
compared with 88.9% (32/36) on non-operated sides, P=0.735. 
In the third (III) and fourth (IV) papers SLNB in the neoadjuvant settting was evaluated in a Swedish 
prospective multicenter trial recruiting women with biopsy-verified breast cancer planned for 
neoadjuvant systemic therapy (NAST). In paper III clinically node-negative (cN0) patients were 
enrolled and SLNB performed prior to commencement of NAST. A completion ALND was 
performed in all patients in both trial arms. The identification rate (IR) was 100% (224/224). The 
proportion of patients with a negative SLNB but still positive lymph nodes in the axilla after NAST 
was 7.4% (9/121, 95%, CI: 4.0-13.5). In paper IV, SLNB was attempted after NAST in 195 patients 
with biopsy-proven node-positive breast cancer at stage T1-4d. The overall IR was 77.9% (152/195) 
and the overall FNR 14.1 % (13/92). The FNR decreased to 4.0% when two or more SLNs were 
retrieved. 
Conclusions: Positive SLNs are rare in pure DCIS. SLNB should only be performed if mastectomy is 
planned or in case of high risk of invasive disease if breast-conserving surgery is planned. SLNB after 
prior diagnostic surgery seems accurate with minor impact on lymph drainage patterns. SLNB in cN0 
patients before NAST is highly reliable. SLNB after NAST in clinically node-positive patients with 
T1-4d stage breast cancer is feasible but associated with lower IR and higher FNR than in clinically 
node-negative patients. Only if two or more SLNs are retrieved can the omission of ALND be 
considered.  
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1 INTRODUCTION 
________________________________________________________________________ 
I was introduced to the field of research by Fuat Celebioglu, the head of the Breast Surgical 
Unit at Södersjukhuset in 2009, less than a year after having started my subspecialisation on 
breast surgery. At that time, my children were five and two years old respectively and if had 
known then, what I know now, namely how much precious time, effort and sacrifices it takes 
to become a doctor of philosophy, I am not sure that I would have accepted the invitation. 
Even though there has been a lot of hard work along the way, I am glad that I decided to 
embark opon this long journey. 
In September 2009, I myself together with Fuat Celebioglu, professor Jan Frisell, Karolinska 
University Hospital Solna and professor Leif Bergkvist, Västerås Hospital met for the first 
time to discuss the study design for a new national research trial. They are all senior breast 
surgeons with a scientific special interest in SLNB in breast cancer. Fuat Celebioglu was to 
become my main supervisor and professor Jan Frisell my first co-supervisor.  
 This was the start of the Swedish prospective multicenter trial with the aim of evaluating the 
feasibility and timing of SLNB within the neoadjuvant setting in breast cancer, as requested 
by the Swedish Society for Breast Surgery. The study opened for accrual in October 2010 and 
did not close until the end of December 2015 after having reached its accrual goal. The 
results of this study formed the basis for papers III and IV.  
I became a registered doctoral student in October 2011 and the year before, I was introduced 
to professor Rimma Axelsson, Department of Radiology, Karolinska University Hospital 
Huddinge, who became my second co-supervisor. She had been collaborating with Fuat 
Celebioglu in research projects investigating lymph drainage patterns evaluated with 
scintigraphic imaging after axillary surgery. Professor Axelsson and Fuat Celebioglu had 
plans for a new study investigating lymph drainage alterations after a surgical breast biopsy 
evaluated with hybrid SPECT/CT imaging. The results of this project formed the basis for 
paper II.  
Last but certainly not least, professor Jan Frisell introduced me to his breast surgical 
colleague, associate professor Jana de Boniface, my third co-supervisor. She had started to 
collect data from the Swedish National Breast Cancer Registry to be used for a retrospective 
study with the principal aim of investigating the incidence of SLN metastasis in women with 
a postoperative diagnosis of pure DCIS. DCIS is a precancerous entity of breast cancer 
theoretically not able to metastasize. The results of this project formed the basis for paper I.  
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2 BACKGROUND 
________________________________________________________________________ 
2.1 ANATOMY OF THE BREAST 
The breast starts to develop during fetal week six as a thickening on the chest called the 
mammary ridge or milk line. Several epithelial buddings develop along the milk line but only 
two remain and by the time the baby is born two nipples and the beginning of a duct system 
with 15-20 main ducts have formed. At puberty the female breast enlarges slowly under 
influence of estrogens from the ovaries and the duct system continues to branch and grow. In 
addition, fat and fibrous tissue will grow in between the mammary ducts. Fibrous septa 
within the breast, continuous with the underlying deep fascia, develop and function as an 
“inner bra” giving support to the breast. These septa or suspensory ligaments are called 
Cooper’s ligaments. The breast is richly vascularized from several arteries. The majority of 
the blood is delivered by perforants from the internal mammary artery. The venous blood 
follows the arteries and drains into the internal thoracic and axillary veins. There are several 
nerves that run within the axillary region at risk of getting injured during axillary surgery. 
The thoracicus longus nerve innervates the anterior serratus muscle and an injured nerve will 
result in a winged scapula. The thoracodorsal nerve innervates the latissmus dorsi muscle 
which is involved in adduction and extension of the arm. There are also intercostobrachial 
sensory nerves innervating the skin in the lateral aspect of the axilla and the medial part of the 
upper arm.  
It is not until the completion of the first pregnancy that the breast matures fully with further 
branching and growing of the ducts into lobes and smaller lobules and finally at their ends, 
the secretory alveoli where the milk production takes place. The breast parenchyma consists 
of 15-20 lobes, each draining into a major lactiferous duct which dilates to as sinus behind the 
areola. When lactation ceases the glandular tissue regresses but not as far as to the pattern 
before the first pregnancy. This process continues after the menopause with further loss of 
alveoli and reduction of the duct system (involution) and eventually the glandular tissue is 
mostly replaced by fat [1]. 
2.1.1 The lymphatic system 
The primary function of the lymphatic system is to drain interstitial fluid from small blind-
ending lymphatic capillaries consisting of a single layer of endothelial cells. An osmotic 
pressure gradient and smooth muscle contractions generate lymph flow. Lymphatic 
capillaries drain into precollectors containing valves helping to direct the lymph which in turn 
drains into afferent lymphatic vessels on the cortex of the lymph nodes. Throughout the 
lymphatic system, lymph nodes are distributed, functioning as filters. The lymph leaves the 
node from the hilum in efferent lymphatic vessels that drain into larger collecting vessels 
which in turn eventually reach the thoracic duct or the right lymph duct before draining into 
the venous circulation via a jugular anastomosis [2]. 
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Figure 1 Anatomy of the breast. Reproduced with permission from Komen Greater NYC. 
Since the introduction of the sentinel lymph node biopsy (SLNB) technique, there has been 
an increased interest in the lymphatic system and lymph drainage from the breast. The lymph 
vessels in the breast are arranged in a superficial and a deep lymphatic system. The 
superficial lymphatics in the skin and nipple communicate with a subareolar lymphatic 
plexus. According to studies by Sappey in the 1830s using mercury injections in the 
lymphatic system [3], lymph from deeper parts within the breast tissue drain centripetally into 
the subareolar plexus on its way to the axilla. Later, studies by Turner-Warwick in 1959 using 
colloidal gold, show that the deep lymphatics in the breast parenchyma arising from the 
lobules, to some extent also drain directly to the axilla without first passing through the 
subareolar plexus, although connections between the deep and superficial collecting lymph 
vessels exist [4]. In addition, about 20% of the lymph in the deep lymph vessels follow 
branches of the internal thoracic artery and drain into the parasternal internal mammary chain 
nodes [5]. The ipsilateral axillary lymph nodes receive about 75 % of the lymph from the 
breast and are the most common site for metastases from a breast cancer [1]. Other less 
common drainage routes are to the ipsilateral internal mammary, supraclavicular and 
posterior intercostal nodes and less frequently to the contralateral parasternal or axillary 
nodes [6].  
The axillary lymph nodes are usually grouped into level I (below and lateral to the pectoralis 
minor muscle), level II (behind the pectoralis minor muscle) and level III (medial to the 
pectoralis minor and below the clavicle).  
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2.2 EPIDEMIOLOGY AND RISK FACTORS FOR BREAST CANCER 
Breast cancer is the most common cancer in women in the western world and accounts for 
approximately 30% of female malignancies. The incidence is high in Northern Europe, North 
America and Australia and low in Asia and Africa but has increased globally over the last 
decades, especially in high income countries [7]. The increase has been ascribed to altered 
reproductive patterns (such as later age at first birth and less use of breast-feeding), increased 
use of menopausal hormone replacement therapy (HRT) and mammography screening 
programmes. During the latest 20 years, the annual increase in incidence in Sweden has been 
1.6%. The largest increase is seen in women aged 60-69 years [8]. The median age at 
diagnosis is 65 years. Time trends for incidence and mortality for female breast cancer is 
shown in Figure 2 below.  
  
Figure 2 Time trends in incidence and mortality for female breast cancer in Sweden.  
Data from NORDCAN (Association of the Nordic Cancer Registries). 
In 2015, 7963 women and 59 men were diagnosed with breast cancer in Sweden [9]. 
Mortality has slightly decreased over the last two decades, thanks to earlier detection through 
mammography screening and improved adjuvant treatment. There were 1400 breast cancer-
related deaths among women in Sweden in 2011 [10].  
The causes of breast cancer are not fully understood but there are several risk factors known 
to affect the likelihood of developing breast cancer, some more significant than others.  
 6 
Being of the female sex greatly increases the risk of developing breast cancer. Age also 
represents a strong risk factor, as approximately 5% of all breast cancer affects women less 
than 40 years of age [10].  
After sex and age, a family history of breast cancer is one of the strongest risk factors. Having 
a first degree relative with breast cancer doubles the risk, especially if there is low age at 
onset [11]. Families with three or more close relatives in two generations with breast- or 
ovarian cancer are regarded as having hereditary breast cancer, accounting for 5-10% of 
breast malignancies. An inherited disorder in tumor suppressor genes BRCA 1 or BRCA 2 
accounts for 2.5-5% of all incidental breast cancer. The life-time risk of developing breast 
cancer for carriers of these high penetrance gene mutations is 50-80% and for ovarian cancer 
25-60% with the higher risks for BRCA 1 mutation carriers [12]. 
High mammographic density increases the risk four to six-fold compared with women with 
fatty breasts. Mammographic density changes with age, parity and weight and can be reduced 
with tamoxifen, which is associated with a better prognosis [13, 14]. 
Proliferative lesions in the breast, especially if atypia is present can significantly increase the 
risk of malignant lesions [15].  
A high endogenous estrogen level stimulates breast epithelial proliferation and several risk 
factors are related to reproductive and hormonal factors such as early menarche, late 
menopause, nulliparity or having the first child after age thirty [16]. Giving birth to many 
children and breast-feeding each child for more than six months are both protective and 
reflects the lower incidence in developing countries [7].  
Exogenous hormone intake like HRT during the menopause is a well-known risk factor, 
especially if estrogen is combined with progesterone and taken for a period of five years or 
more [17]. Oral contraceptives are believed to marginally increase the risk [16].  
Extrinsic factors associated with lifestyle also influence the risk. Postmenopausal obesity, low 
physical activity and high alcohol consumption all increase the risk [18]. Previous chest 
radiotherapy increases the risk six-fold in young women as seen in survivors after Hodgkin´s 
lymphoma [19]. 
2.3 TUMOR CLASSIFICATION 
2.3.1 TNM classification 
Stage is the most important prognostic factor in cancer and is determined from information 
on the tumor (T), regional lymph nodes (N) and metastases (M). The TNM system is the 
most used staging system worldwide and is revised every 6-8 years by the American Joint 
Committee on Cancer (AJCC) in collaboration with the Union for International Cancer 
Control (UICC) [20]. Stage is defined at different points in cancer treatment. Clinical stage 
(pre-treatment stage) is any information about the extent of cancer before initiation of 
treatment or within four months from diagnosis “prefix c” (cT, cN, cM). Clinical stage is 
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defined by clinical examination or imaging. Pathologic stage is based on information from 
histopathological examination of surgically removed tissues at primary definitive surgery 
“prefix p” (pT, pN, pM).  
The post-therapy stage, documents the extent of disease after neoadjuvant systemic therapy 
initiated before surgical resection, or sometimes without surgical resection. It can either be 
based on clinical and/or radiological examination (ycT, ycN, ycM) or be based on 
postoperative pathological findings (ypT, ypN, ypM) [21]. 
Prognosis and survival is closely related to stage at diagnosis. The 5-year survival rate is 
almost 100 % in stadium 0-1(T<2 cm and N0), 80 % in stadium II (T<5cm and N1 or T>5 
cm and N0), 60% in stadium III (T any size and N 1-3) and only 20 % in stadium IV (any T, 
any N, M1) [18]. The 5-year relative survival rate (excluding stadium IV) has increased from 
approximately 65% in the 1970s to 91% in 2015 [9].  
2.3.2 Histological grade 
Histological grade is also a strong prognostic factor and the morphological grading system 
described by Bloom and Richardson in 1957 [22], was modified by Elston and Ellis in 1991 
to make the criteria more objective. The overall grade (I-III) is derived from the summation 
of scores from three morphological features; degree of tubular formation (1-3), nuclear atypia 
(1-3) and mitotic count (1-3). Histological grade together with tumor size and lymph node 
stage form the Nottingham prognostic index (NPI) which is used to determine prognosis after 
breast surgery [23]. 
2.3.3 Histopathologic type 
Breast cancer is divided into invasive and non-invasive cancers. The latter is also called 
carcinoma in situ (“in the same place”), which means it does not invade surrounding tissues. 
2.3.3.1 Invasive breast cancer 
According to the fourth update of the WHO classification of breast cancer, the terminology 
for the most common type of breast cancer has changed from invasive ductal carcinoma to 
invasive carcinoma of no special type (NST). The reason for this is uncertainty of ductal 
origin and that this does not represent a uniform group of carcinomas. Invasive carcinoma 
(NST) accounts for 50-80 % of all invasive breast cancer [24]. Among the specific subtypes, 
lobular carcinoma is the most common form (5-15 %). Immunostaining for the 
transmembrane protein e-cadherin, which mediates cell-cell adhesion is mostly negative and 
can help distinguish it from NST [25]. Tubular, medullar, metaplastic, mucinous and 
papillary carcinomas are all special forms with different prognoses, each occurring in 
approximately1-2% of all invasive breast cancer [24].  
Inflammatory breast cancer (IBC) is a rare but very aggressive entity of breast cancer. The 
overall five-year survival rate is approximately 30% despite current improvements in therapy. 
Unfortunately, there are no molecular criteria distinguishing it from non-inflammatory breast 
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cancer, which would have enabled development of more efficient targeted therapies [26]. The 
diagnosis is clinical and requires the presence of typical clinical features including; rapid 
breast enlargement with a diffuse erythema and edema (peau d´orange) of more than a third 
of the breast skin, and often with a diffuse firmness is in the breast. The presence of tumor 
emboli within dermal lymphatics is supportive but not sufficient for diagnosis according to 
the AJCC’s cancer staging manual [21]. 
2.3.3.2 In situ breast cancer 
Since the introduction of mammography screening programmes in the mid 1980s, the 
incidence of ductal carcinoma in situ (DCIS) has increased tremendously. DCIS was 
previously considered a rare condition diagnosed incidentally at biopsy or symptomatically in 
the form of a breast lump, nipple discharge or presenting as Paget´s disease of the nipple. 
Today, DCIS accounts for approximately 10% of all newly diagnosed breast cancer and 
approximately 20% of all screening-detected breast cancer in Sweden [8], owing to typical 
microcalcifications often accompanying DCIS visible on mammograms [27].  
The 4
th 
edition of theWHO Classification of Tumors of the Breast manual, lists DCIS and 
lobular neoplasia (LN) as precursor lesions of breast cancer. LN is further subgrouped into 
lobular carcinoma in situ (LCIS) and pleomorphic lobular carcinoma in situ (PLCIS), the 
latter being a more aggressive entity. The third lobular entity is the atypical lobular 
hyperplasia (ALH), separated from the other two by the degree of involvement of the acini 
[24]. LN is a risk factor for invasive disease in both breasts, but the vast majority of lesions 
will never progress to invasive breast cancer [28]. Apart from excision with free margins no 
other treatment is recommended than regular mammography controls [18]. 
DCIS is a heterogenous pre-invasive form of breast cancer in which the proliferating 
epithelial cells are confined to the mammary ducts without breaking through the basal 
membrane and therefore theoretically cannot infiltrate the surrounding tissue and metastasize. 
The traditional classification was based on growth pattern. However, nuclear grade correlates 
better with recurrence risk and is more easily reproduced. There are different classification 
systems based on nuclear grade and most have three groups: low, intermediate and high grade 
DCIS. In Sweden, grading by Holland is used, which takes into account cell polarization, 
necrosis and type of calcifications in addition to nuclear grade. The highest grade (grade III) 
is the most aggressive type [29]. Comedo necrosis is more common in high grade DCIS but is 
not mandatory [30]. Atypical ductal hyperplasia (ADH) is a proliferative lesion often difficult 
to distinguish from low grade DCIS on preoperative needle biopsies [24]. The natural history 
of DCIS is not fully known, but according to a review of studies reevaluating large amounts 
of breast biopsies initially considered benign and later reclassified as DCIS, the risk of 
progression to invasive breast cancer over a period of ten years is 14-53% [31]. Local 
recurrences generally occur at the site of the previous breast excision and invasive 
recurrences are equally common as in situ. However, young women have a higher risk for a 
subsequent invasive breast cancer [32].The most important factor in reducing the risk of local 
recurrence in DCIS is complete excision with clear margins [33].  
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Microinvasive carcinoma infiltrates across the basement membrane at one or two locations 
each measuring less than 1mm in its greatest dimension and is usually seen in extensive 
DCIS especially of high grade [24]. 
2.3.4 Biomarkers  
Imunohistochemical (IHC) analysis of protein gene products; ER, PgR, HER2 and Ki-67, are 
routinely assessed in breast cancer and are important prognostic but also predictive factors, 
helping to predict sensitivity to treatment [34]. The Swedish Breast Cancer Group 
(SweBCG), KVAST (The Swedish National Guidelines for Pathologists working group), 
Swedish Quality Assurance (SweQA) together with Equalis perform important quality 
assessment. Reproducibility studies are performed using reference samples distributed to 
different pathology departments in Sweden to assure quality and comparability between 
analyses from different laboratories. The reproducibility for ER, PgR and HER2 is high 
(kappa value 0.8) while it is unsatisfying for Ki-67 (kappa 0.6) [18]. There are national and 
international collaborations working to improve concordance in Ki-67 scoring [35]. 
2.3.4.1 Estrogen receptor (ER) 
The estrogen receptor (ER) was the first candidate for a specific targeted therapy in breast 
cancer. Approximately 80-85% of women with invasive breast cancer are ER-positive and 
more or less sensitive to endocrine therapy [9]. There are two isoforms of ER (ERα and 
ERβ). ERα is the clinically used isoform and is located in the cell nucleus. The role of ERβ in 
breast cancer is under much investigation. Its impact on prognosis seems favorable but can 
differ between treatment groups [36]. The primary ligand is 17-β-estradiol which binds to the 
receptor and stimulates cell growth by transcription [34]. The most commonly used threshold 
for ER-positivity has been 10% but in 2010 the American Society of Clinical Oncology 
(ASCO) and the College of American Pathologists (CAP) recommended that ER and 
Progesteron receptor (PgR) assays with at least 1% positive tumor nuclei should be 
considered positive [37]. However, in a retrospective study based on 9639 women, those with 
1-9% ER-positivity did not seem to benefit from endocrine therapy [38].  
2.3.4.2 Progesteron receptor (PgR) 
The progesterone receptor (PgR) also exists in two isoforms (PgRα and PgRβ) but distinction 
is not possible since available antibodies bind to the N-terminal part common to both 
isoforms. PgR-status is an independent prognostic factor in breast cancer. In a population-
based study, PgR negativity was associated with a significantly poorer prognosis in ER-
positive node-negative patients receiving endocrine therapy [39]. ER-negative but PR-
positive breast cancers are rare and it is not clear if it is a distinct biological entity or a 
technical artifact since gene expression of PgR is dependent on estrogen, indicating an intact 
estrogen-ER-signalling pathway [40].  
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2.3.4.3 HER 2neu/ERBB2  
Human epidermal growth factor (HER) 2 is a tyrosine kinase receptor located on the cell 
surface. Approximately 15% of all breast cancers overexpress HER2 [9]. HER2-status is 
assessed with immunohistochemistry followed by in situ hybridization if amplification is 
suspected. Patients with HER2-positive breast cancer have poorer prognosis with shorter 
overall survival. However, since the development of trastuzumab (Herceptin®), a 
monoclonal antibody targeted against HER2, the prognosis has improved dramatically and is 
similar to the prognosis in patients with hormone receptor-positive breast cancer [41].  
2.3.4.4 Ki-67 
Ki-67 is a monoclonal antibody directed against an antigen (Ki-67 protein) expressed only in 
proliferating cells. High Ki-67 is a prognostic marker but clinical validation has proved 
difficult [42]. It is a continuous index of the fraction of proliferating tumor cells. High and 
low values are reproducible and clinically useful, but there is no standardized cut off level for 
intermediate values [35, 43]. MIB-1 is another monoclonal antibody directed against the 
same antigen. It can also be used on formalin-fixed paraffin-embedded sections [44]. 
2.3.5 Molecular subtypes 
Classification of breast cancers into “intrinsic subtypes” based on gene expression patterns 
using cDNA microarrays and hierarchical clustering can be used to predict survival and how 
well a cancer will respond to a certain treatment [45, 46]. There are commercially available 
multigene assays, such as Oncotype DX® or Mammaprint®, that divide tumors into different 
risk groups based on their gene expression patterns in a number of selected genes. Especially 
in patients with a good prognosis as in ER-positive node negative breast cancer, these tests 
can help in deciding who might benefit from adjuvant chemotherapy or not [47]. Since these 
tests are expensive and not available for most people around the world, surrogate molecular 
subtypes based on IHC tests (ER, PgR, HER2 and Ki-67) are used to guide treatment 
decisions. According to the 13
th
 St. Gallen International Breast Cancer Conference [48], the 
definitions are as follows: 
Luminal A-like:  ER pos, PgR pos, HER2 neg, Ki-67 low 
Luminal B-like (HER2 negative):  ER pos, HER2 neg and either Ki-67 high or PgR neg 
Luminal B-like (HER2 positive):  ER pos, HER2 pos  
HER2 positive (non-luminal):  ER neg, PgR neg, HER2 pos  
Triple negative (ductal):  ER neg, PgR neg, HER2 neg  
2.4 DIAGNOSIS 
The investigation of clinically suspicious findings in the breast relies on the combination of 
physical examination, radiological imaging (mammography and/or ultrasound) and needle 
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biopsy (fine or core). This clinical work up is usually called triple assessment and has a 
sensitivity close to 100%. If after triple assessment, any doubt remains, as to whether the 
lump is malignant or not, a diagnostic surgical breast biopsy is recommended [18]. In 
Sweden, over 90% of breast cancers are diagnosed preoperatively and a high proportion of 
patients are discussed at both pre- and postoperative multidisciplinary conferences according 
to the Swedish National Breast Cancer Registry [9].  
In addition to mammography and ultrasound, there are other complementary radiological 
examinations performed in special situations. Breast MRI (magnetic resonance imaging) is 
recommended for screening women with inherited susceptibility for breast cancer. In 
especially young women with dense breasts, MRI has higher sensitivity than mammography 
and ultrasound. However, the specificity is fairly low, and false-positive findings might lead 
to diagnostic breast excisions or more extensive surgery. A Swedish prospective multicenter 
study randomized 440 breast cancer patients to preoperative MRI of the breast (POMB) or 
not, in addition to conventional imaging. The authors found no significant differences in 
mastectomy rates between groups. The intervention group had a higher degree of 
preoperative conversion to mastectomy from breast-conserving surgery but the reoperation 
rate was significantly reduced in the MRI group compared with the control group [49]. MRI 
is the recommended imaging tool for response evaluation during and after neoadjuvant 
systemic therapy. According to a review by Fumagalli et al, ultrasound and mammography 
should only be used if MRI is not available [50]. In a meta-analysis by Marinovich et al, MRI 
was found to be more accurate than mammography in detecting residual tumors, although not 
superior to ultrasound. The authors concluded that further comparative studies are needed 
[51].  
Mammography screening was introduced in Sweden in 1986 and ten years later it was 
implemented nationally. The National Board of Health and Welfare (Socialstyrelsen) 
recommends mammography screening between ages 40-74 with an interval of 18-24 months 
[52]. The recommendations are based on several Swedish randomized trials which have 
shown reduced mortality rates of 20-25% for women participating in screening programmes 
[53, 54]. However, there is an ongoing debate where critics claim that the benefits of 
mortality reduction is prevented by overdiagnosis and overtreatment [55]. The sensitivity of 
mammography in the screening situation is lower and varies in relation to factors of body 
weight and how fatty or dense the breasts are [56]. In the screening ages (40-74), 
approximately 64% of all incidental breast cancers are screening-detected corresponding to 
just above half of all detected breast cancers in Sweden [9]. Screening-detected breast cancer 
has a more favorable prognosis due to earlier detection and better tumor biology [57]. 
2.5 BREAST SURGERY 
William Halsted, at John Hopkins Hospital, in 1882 performed the first radical mastectomy 
removing not only the whole breast but also the underlying pectoralis major and minor 
muscles together with most of the ipsilateral axillary lymph nodes. This extensive surgery 
was necessary according to the Halstedian model of cancer progression in which tumors grow 
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locally, then spread to the regional lymph nodes and finally from there to the rest of the body 
[58]. The radical mastectomy was the prevailing breast cancer surgery until the 1970s and 
although it resulted in significantly reduced rates of local recurrence, it was associated with 
immense morbidity in terms of disfigurement, pain, massive lymphedema, restricted shoulder 
mobility and sensory loss [59]. 
In 1948, David Patey described for the first time a modification of Halsted’s radical 
mastectomy in which the pectoralis muscles were spared together with some of the axillary 
lymph nodes (level III), and despite a much less extensive cancer surgery, the survival rates 
were comparable [60]. Halsted’s model of tumor progression failed to explain the occurrence 
of distant metastases in women who had been successfully treated with this extensive 
surgery. Instead the systemic theory developed by Geoffrey Keynes, but fully stated by 
Bernard Fisher in 1980, won acceptance. According to this theory, local control is not 
sufficient to impact survival since there is no orderly pattern of tumor cell dissemination [61]. 
Today breast cancer is thought of as a heterogenous disease, spanning from patients with 
lymph node metastasis being the only site of dissemination with good prognosis after surgery 
alone, to others where nodal involvement is only a marker of an already disseminated disease 
[62, 63]. The modified radical mastectomy developed by Patey, is the method a mastectomy 
is still performed today. 
Breast-conserving surgery (BCS) was introduced in the 1960s and is the primary surgical 
treatment for small to medium sized breast cancers. Approximately 77% of all newly 
diagnosed breast cancers less than 3 cm in size are removed with BCS in Sweden [9]. 
Provided radiotherapy is part of the breast-conserving therapy, survival rates are comparable 
to mastectomy. This statement is based on several randomized multicenter trials with over 
twenty years of follow-up [64, 65]. Although local recurrence rates are higher after BCS, the 
long-term overall survival is comparable [66]. Risk factors for local recurrence are young 
age, multicentricity and unclear/unknown surgical margins [67]. A consensus guideline based 
on a meta-analysis from a systematic review of 33 studies including 28162 patients, 
concluded that positive margins increase the risk two-fold for an ipsilateral local recurrence 
compared with negative margins. However, wider surgical margins than negative, do not 
significantly decrease the recurrence risk in invasive breast cancer [68].  
2.6 AXILLARY SURGERY  
Axillary surgery is primarily performed for nodal staging. Lymph node status is still one of 
the most important prognostic factors in breast cancer, despite advances in biomarkers and 
gene expression analysis, and strongly influences therapy decisions [62]. Axillary surgery 
also provides locoregional control and prevents axillary recurrences. When it comes to 
survival, earlier randomized studies have not been able to show any convincing survival 
benefits with axillary dissection in clinically node-negative patients with early-stage breast 
cancer [69, 70].  
 13 
Lymph node metastases are divided into macrometastases (pN1) containing tumor deposits 
larger than 2 mm and micrometastases (pN1mi) with tumor deposits larger than 0.2 mm but 
not above 2 mm in size. Smaller tumor deposits, up to 0.2 mm, are called isolated tumor cells 
(ITC) (pN0i+) and these lymph nodes are classified as node-negative (pN0) [71]. There is a 
relationship between the number of positive lymph nodes and the outcome [72]. 
Efforts to predict axillary lymph node status based on clinical or biological tumor information 
has so far not been able to replace surgical nodal staging. In a study investigating 1300 
consecutive patients, multivariate analysis found lymphovascular invasion, tumor size, 
retroareolar or lateral tumor location and multifocality to be the strongest predictors of 
axillary lymph node metastasis [73]. Neither physical examination [74] nor attempts with 
different imaging modalities, such as ultrasound with or without fine needle aspiration 
cytology [75, 76], MRI [77], or positron emission tomography (PET) [78], have so far proven 
to be sensitive enough to replace surgical nodal staging. However, if no suspicious lymph 
nodes are detected with ultrasound, more heavy disease burden can be ruled out with 
relatively high certainty [79]. 
2.6.1 Axillary lymph node dissection 
Axillary lymph node dissection (ALND) levels I and II, has been the standard axillary nodal 
staging procedure in breast cancer since the introduction of the modified radical mastectomy. 
With the correct surgical technique, the axillary lymph node yield should be at least ten 
lymph nodes, which is recommended to avoid misclassification. A large Danish study found 
that if fewer than ten negative lymph nodes were retrieved, this resulted in incorrect nodal 
staging with significantly higher recurrence rates and poorer survival outcomes [80].  
However, axillary surgery and especially ALND, is associated with potential arm morbidity 
including seroma formation, nerve damage, paresthesia, chronic pain, impaired shoulder 
mobility and not to mention lymphedema [81, 82]. Lymphedema can develop secondary to 
axillary surgery, due to scarring and disruption of lymph vessels resulting in impaired lymph 
transport capacity. This leads to collections of lymph fluid and proteins in the interstitium that 
in turn attract more fluid. Eventually the fluid is replaced by adipose tissue [83]. 
Radiotherapy further increases the risk of lymphedema [84]. The incidence of lymphedema 
after ALND varies dramatically between studies and is dependent on how lymphedema is 
defined and measured, as well as the duration of follow-up [85]. In addition, objectively 
measured lymphedema may differ from self-perceived discomfort and health-related quality 
of life [86]. After the introduction of mammography screening, the proportion of patients 
with node-positive breast cancer at diagnosis has decreased to approximately 30% in early-
stage breast cancer [87]. In this situation, alternative less extensive surgical staging methods 
were developed. One of them was axillary sampling, comprising of four or five randomly 
harvested and analyzed axillary lymph nodes from level I. In Sweden, Ahlgren et al 
performed a prospective study evaluating 450 patients. The sensitivity was 97% and the 
negative predictive value was 98% [88]. Despite this and some other studies with rather 
promising results, axillary sampling has been difficult to implement outside of a clinical trial 
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setting [1]. There have also been attempts to completely avoid axillary surgery in selected 
individuals with low-risk, often elderly women with small hormone receptor-positive tumors. 
In a review and meta-analysis evaluating two randomized controlled trials in elderly women, 
those women in whom nodal staging was omitted, had significantly more regional 
recurrences, but overall and disease-free survival was not inferior [89].  
2.6.2 Sentinel lymph node biopsy 
2.6.2.1 Sentinel lymph node biopsy concept 
The sentinel lymph node (SLN) is the first lymph node or nodes that receive(s) lymph fluid 
from a primary tumor and if this or these nodes are free of tumor cells, the other sequential 
draining lymph nodes are also free of metastasizing cancer cells with high certainty hence the 
patient can be spared further nodal dissection. For the breast, the SLN is usually located in the 
axilla at level I, lateral to the pectoralis minor muscle, but can also be located higher up in the 
axilla or in the parasternal lymph nodes.  
2.6.2.2 Sentinel lymph node history 
The term “sentinel node” was first mentioned by Gould et al in 1960 to describe a lymph 
node situated at the junction between the anterior and posterior facial vein. This lymph node 
was analyzed intraoperatively and could predict the neck nodal status in patients with cancer 
in the parotid gland [90]. The sentinel node concept was introduced clinically by Cabanas in 
1977 in penile cancer. In 1992 Morton et al used blue dye to identify the draining lymphatic 
ducts from melanomas [91]. In 1993 Krag described the use of radiolabelled colloid and 
intraoperative detection of the SLN with a hand-held gamma probe [92]. The year after, 
Guiliano et al first described blue dye mapping in breast cancer [93]. The SLN technique was 
introduced in the late 1990s into clinical practice worldwide, as a less extensive nodal staging 
procedure in breast cancer, with significantly less morbidity compared with ALND. Patients 
with a negative SLNB could be saved the morbidity associated with ALND [82, 94, 95]. The 
sentinel lymph node mapping technique is illustrated in Figure 3.  
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Figure 3 The sentinel lymph node mapping technique.  
Reproduced with permission from IntraMedical Imaging LLC. 
2.6.2.3 Sentinel lymph node mapping 
There has been a lot of debate concerning different technical issues and their impact on 
identification rate (IR) and false negative rate (FNR), such as choice and dose of blue dye and 
radioactive tracer, particle size and type of the carrier protein for the radioactive tracer, and 
further where in the breast to inject them and how deep. There is consensus that the 
combination of blue dye and radiolabelled colloid (dual mapping) gives the best sensitivity 
for finding nodal metastases in most institutional settings [96]. The blue dyes mostly used are 
Patent Blue V, Isosulfan Blue and more rarely Methylene Blue. Blue dyes can give rise to 
anaphylaxis in approximately 1% of procedures [97] and are therefore contraindicated in 
pregnant women. The standard radioactive tracer is 
99m 
Technetium which has a half-life of 
six hours that makes it vulnerable in terms of storage and distribution. There has been a 
worldwide shortage of Technetium and in addition, the radioactive tracer is associated with 
radiation exposure, hence there is an ongoing search for alternative and preferably 
nonradioactive substances [98].  
A novel technique using a magnetic tracer, supraparamagnetic iron oxide (SPIO), has been 
evaluated in a number of trials. According to a systematic review and meta-analysis the 
accuracy is not inferior to the standard technique and there is no radioactivity involved. 
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However, significantly more SLNs are retrieved and the iron tracer can leave a brown 
discoloration in the skin at the injection site [99].  
The particle size of the carrier protein has implications for how quickly the radioactive tracer 
is drained to the lymphatic system after injection and how far the radioactive tracer travels in 
the lymphatics. This also influences how many lymph nodes are mapped before the particles 
are trapped. The smaller the colloid, the more secondary lymph nodes will be mapped. The 
optimum colloid size is considered to be 10-100 nm [2]. The most commonly used colloids 
are nanocolloid albumin, sulfur colloid and antimony trisulphide [100]. The radioactive tracer 
is injected into the breast preoperatively on the day of surgery or on the day prior. A higher 
does is required when injecting on the day before surgery. The blue dye is injected in the 
operating theater when the patient is sedated and safely monitored. 
Intraoperatively the surgeon uses a handheld gamma probe to scan the axillary region for 
radioactivity. The skin incision is made in the area indicating the highest counts with the 
probe. The SLN definition mostly used is any blue node or node with a blue afferent 
lymphatic channel, the hottest node and any node with activity >10% of the hottest node and 
in addition, any palpably suspicious lymph node [101]. However, harvesting more than four 
SLNs is of no use since it does not impact the false negative rate (FNR) and will instead 
increase the risk of axillary morbidity and time of surgery [102]. 
The SLNs are sent fresh to the pathology department for histopathological analysis. With 
intraoperative analysis the surgeon can proceed with ALND in the same operation if there is a 
metastasis in the SLNs. Frozen section analysis is the most commonly used method with an 
overall sensitivity of approximately 75%. The sensitivity for micrometastasis is lower even if 
IHC staining is performed [103]. Intraoperative analysis is time-consuming for the 
pathologist and prolongs surgery by approximately 20 minutes. In addition, there is a risk of 
valuable tumor material being lost during the frozen section procedure [98].  
There is a lot of debate and no consensus concerning where in the breast or how deep the 
radioactive tracer and blue dye should be injected. Following anatomical studies by Sappey et 
al, stating that the breast is a single ectodermal unit where the deep lymphatics in the breast 
parenchyma converge through the subareolar plexus on its way to the axillary nodes [3], the 
site of injection should not have any impact on the lymph drainage pattern. However, deep 
peritumoral injections drain to a significantly greater extent to extra-axillary SLNs, in 
particular to the internal mammary nodes in comparison with superficial injections [104]. The 
number and locations of draining SLNs can be visualized preoperatively with a gamma 
camera. Planar lymphoscintigraphy was routinely performed following the introduction of the 
SLN mapping technique. Draining to the internal mammary nodes can be visualized in 5-
17% of patients [105, 106]. Although metastasis to the internal mammary nodes has 
prognostic significance [107], it is unusual with solitary metastasis in these locations and 
harvesting them is technically demanding, adding extra scars and morbidity that is not 
negligible. Therefore, most centers prefer to inject the mapping agents superficially in the 
subareolar plexus and no longer routinely perform preoperative lymphoscintigraphy [108]. It 
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is instead used as a supplement in special situations [98]. In cases with non-visalization on 
planar lymphoscintigraphy, hybrid SPECT/CT imaging can be of additional value since the 
precise anatomical location of SLNs can be visualized [109].  
2.6.2.4 Sentinel lymph node accuracy and safety 
The SLN technique is not only associated with less morbidity than ALND, it is also a more 
accurate and sensitive nodal staging procedure. This is due to all SLNs, in contrast to non-
SLNs, being serial sectioned and examined with IHC staining with antibodies to cytokeratins 
[110, 111].  
There is a learning curve associated with the performance of SLNB [112]. In 2006 a meta-
analysis was published analyzing more than 8000 breast cancer patients from 69 trials treated 
with SLNB and ALND during the validation period between 1970 and 2003. The IR was 
overall 96% with a wide range (41-100%) and the overall FNR was 7.3% also with a wide 
variability (0-29%) between studies [113]. After some years of experience, most studies 
report FNRs between 5-10 %. Despite this fairly high FNR, local recurrences are rare after a 
negative SLNB without ALND, even after ten years of follow-up [114, 115]. There are 
several randomized studies reporting survival data after a negative SLNB not followed by 
ALND and none of them report inferior survival [116]. The largest study, NSABP B-32, 
reports after eight years of follow-up, overall survival rates of 90.3% in the SLNB alone 
group compared with 91.8% in the SLNB and ALND group [117]. SLNB is considered gold 
standard for nodal staging in early-stage clinically node-negative breast cancer [118] and is 
currently recommended also in large [119-121] and multifocal/multicentric tumors although 
the risk of a positive SLNs is higher [122]. 
2.6.2.5 Current controversies with SLNB 
The meticulous examination of SLNs compared with non-SLNs has lead to more and smaller 
tumor deposits being diagnosed. According to current Swedish National Guidelines from 
2014, a complementary ALND should be performed if a micrometastasis is encountered. In 
this years upcoming new guidelines, ALND is not recommended if BCS is planned. Patients 
planned for mastectomy can continue to be enrolled into the Swedish prospective cohort 
study SENOMIC, with the primary endpoint disease-free survival (DFS) after omission of 
ALND (https://sffb.se) [18]. If there is a micrometastasis in the SLN, there is a 10-20% risk 
of finding additional non-sentinel node metastases [123]. A recent large retrospective study 
based on the Surveillance, Epidemiology, and End Results (SEER) database, found that 
micrometastasis in clinically node-negative women was an independent risk factor for breast 
cancer mortality [124]. However, a randomized controlled trial (IBCSG 23-01) did not find 
any significant difference in 5-year DFS between patients with micrometastases in SLNs with 
or without ALND performed. The majority though had BCS, whole-breast radiotherapy and 
adjuvant chemotherapy [125].  
Also the omission of ALND in clinically node-negative patients with one or two 
macrometastases in the SLNs is currently being investigated. There is a 40-65% risk of 
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additional axillary nodal involvement with a positive SLN [126, 127]. The American College 
of Surgeons Oncology Group (ACOSOG) Z0011 multicenter trial randomized 891 clinically 
node-negative patients with T1-2 breast cancer and 1-2 SLN macrometastases to 
complementary ALND or not. All patients had BCS and whole breast irradiation and most 
patients received adjuvant chemotherapy. Although underpowered, after a median follow-up 
of six years, survival was comparable between groups. After nine years, local recurrence-free 
survival was still comparable between groups [128, 129]. Inspired by these results, the 
Swedish-based international SENOMAC trial (www.senomac.se), was launched in 2015 and 
randomizes clinically node-negative patients with maximum two SLN macrometastases to a 
complement ALND or not. The primary outcome measure is breast cancer-specific survival. 
Since the need for ALND has been questioned, also in patients with node-positive disease, 
the need for intraoperative analysis of the SLNs has diminished.  
DCIS is a pre-invasive condition not able to metastasize. However, DCIS is upgraded to 
invasive breast cancer in up to 40% of incidental cases on definitive pathology reports [130]. 
Performing SLNB when mastectomy is indicated for patients with core biopsy-verified DCIS 
is appropriate since SLNB after a mastectomy is technically impossible. However, if BCS is 
planned, SLNB is not recommended according to most international guidelines, given the low 
incidence of positive lymph nodes if signs of potential microinvasion are missing [116, 131]. 
Despite these recommendations, SLNB is still performed to avoid reoperation and maybe 
concerns for a less accurate secondary SLN procedure [9].  
Prior excisional breast surgery might disrupt lymphatics and disturb lymph drainage from the 
breast to the axillary lymph nodes. There has been concern that the mapped SLNs will not 
accurately reflect nodal status in the axilla. Feldman et al reported high FNRs and Borgstein 
et al low IRs. Both used only radioactive colloid injected peritumorally [132, 133]. Patients 
with prior breast surgery were therefore excluded from many of the initial prospective studies 
evaluating SLNB in breast cancer [134]. Later, several studies have shown that SLNB is 
accurate after a previous breast biopsy [135-137].  
There is an ongoing debate on the role and timing of SLNB in the neoadjuvant setting, since 
also patients with operable breast cancer are candidates for neoadjuvant systemic therapy 
(NAST), and only half of them have positive lymph nodes at diagnosis and consequently do 
not benefit from ALND. In addition, current neoadjuvant regimens, including targeted 
therapies if appropriate, achieve nodal downstaging in as high as 70% of patients [138]. It is 
controversial whether SLNB should be performed before or after NAST in clinically node-
negative patients upfront. If performed before, IR is high but the accuracy has mostly been 
captured in small single-center studies omitting ALND if the SLNB was negative [139, 140]. 
SLNB after NAST is associated with lower IR and higher FNR, but only one surgical 
procedure is necessary [141]. In clinically node-positive patients planned for NAST, SLNB 
has been evaluated after NAST, in order to make use of nodal conversion. However, FNR has 
been high in earlier studies ranging from 10-30% and there is a lack of follow- up data [142, 
143]. SLNB is not recommended for patients with inflammatory breast cancer (IBC), not 
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even after nodal downstaging according to ASCO guidelines from 2014 [116]. There are very 
few studies addressing SLNB in IBC and in both studies identified, the authors conclude that 
SLNB is unreliable [144] [26, 116]. 
2.7 SYSTEMIC THERAPY 
The main purpose with systemic therapy is to eliminate micrometastatic disaease and 
circulating tumor cells present at time of diagnosis.  
2.7.1 Neoadjuvant (preoperative) systemic therapy 
Neoadjuvant systemic therapy (NAST) has been used since the 1970s for the treatment of 
inoperable locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC). 
The term LABC includes tumor stage T3 (tumor size>5 cm) or T4abc (tumor of any size with 
direct extension to the chest wall or skin) but does not include inflammatory breast cancer 
(T4d) described earlier. LABC also includes nodal stage N2-N3 (fixed or matted ipsilateral 
axillary, internal mammary or infra/supraclavicular lymph node metastases) [21]. Core-
needle biopsy is mandated before the start of NAST. NAST is either systemic chemotherapy 
or endocrine therapy and is traditionally followed by breast surgery including ALND. After 
surgery, locoregional radiotherapy has been standard concomitant with endocrine therapy in 
hormone-sensitive tumors. Also operable breast cancer is increasingly being treated with 
NAST if adjuvant chemotherapy is indicated. The survival rates are comparable with either 
regime but the advantages are that more patients can be offered BCS due to downstaging, 
chemosensitivity can be evaluated in vivo and treatment changed if response is lacking or 
progress occurs [145, 146]. Additionally, NAST facilitates rapid drug development and 
approval [147]. With current chemotherapy in combination with targeted anti-HER2 drugs, 
pathological complete response (pCR) in breast and nodes (ypT0/is/N0) can be achieved in as 
high as 70% of patients. Patients who achieve pCR have a better survival rate compared with 
those having residual disease. The association is dependent on tumor subtype and is strongest 
for patients with HER2-positive and triple-negative tumors [138, 148]. In ER-positive breast 
cancer, neoadjuvant endocrine therapy may be an option, especially in frail elderly women. 
Aromatase inhibitors are more efficient than tamoxifen. If the disease is stable, treatment 
duration can be life-long if surgery is not suitable or desirable [149]. In 2015, neoadjuvant 
instead of adjuvant chemotherapy was given to 19% (range 4-26%) of newly diagnosed 
Swedish breast cancer patients [9]. 
2.7.2 Adjuvant chemotherapy  
Chemotherapy has been in use since the 1960s, initially in patients with breast cancer 
recurrence[150]. Adjuvant therapy is given in addition to primary surgery with curative intent 
to patients with regional lymph node metastasis but also to node-negative patients with ER-
negative tumors or if other risk factors such as young age, high grade, high proliferation or 
lymphovascular invasion are present [18]. The surrogate molecular subtypes are, besides 
nodal status, the most important factors for therapy planning. A meta-analysis on behalf of 
the Early Breast Cancer Trialists´ Collaborative Group (EBCTCG) including 123 randomized 
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trials and 100.000 patients, showed that adjuvant polychemotherapy with high-dose 
antracyclines are more efficient than earlier CMF-combinations although associated with 
more cardiac toxicity. The addition of taxanes to anthracyclines was even more efficient and 
10 year breast cancer mortality could be reduced by about one third. The relative benefit with 
chemotherapy was not dependent on age, tumor size, nodal stage, grade, ER-status or 
tamoxifen use. However, the absolute gain was proportional to an individual´s risk without 
chemotherapy [151].  
2.7.3 Targeted therapy 
HER2-positive patients left untreated have a worse prognosis. Trastuzumab given together 
with chemotherpy in early breast cancer, improves survival significantly (hazard ratio 0.66) 
and 1 year of trastuzumab is now standard in HER2-positive breast cancer larger than 5 mm 
in size [35, 152] but the risk for congestive heart failure is substantial [153]. In the 
neoadjuvant setting, HER2-positive patients who receive trastuzumab in combination with 
pertuzumab and taxanes, achieve significantly higher pCR rates compared with 
chemotherapy and trastuzumab alone [154, 155]. 
2.7.4 Adjuvant endocrine therapy 
Approximately 80% of breast cancer patients have ER-positive tumors, the growth of which 
is stimulated by hormones. Adjuvant endocrine therapy either blocks or lowers the circulating 
endogen hormone levels, thereby reducing both local and distant recurrences. They are 
administered following chemotherapy since they decrease the proportion of proliferating 
cells, making the tumor less sensitive to chemotherapy. In ER-positive patients, five years of 
tamoxifen reduces recurrence rates by about half and breast cancer-specific mortality by one 
third during the first 15 years after the start of treatment [156]. Extending tamoxifen to ten 
years can further reduce recurrence rates and DFS but compliance is a problem that needs 
attention [18]. Aromatase inhibitors are first choice in postmenopausal women with high-risk 
tumors owing to more efficient local control compared with tamoxifen, even though the 
effects on mortality are uncertain [157].  
2.8 ADJUVANT RADIOTHERAPY 
According to international guidelines from the European Society of Breast Cancer Specialists 
(EUSOMA) and the American Society for Radiation Oncology (ASTRO), radiotherapy is 
indicated if the local recurrence risk exceeds 20% within 10 years. This applies for women 
after BCS, after mastectomy if the tumor is larger than 5 cm, and in case of four or more 
positive axillary lymph nodes [158].Whole breast irradiation is part of the therapy for patients 
with invasive breast cancer having BCS and reduces the local recurrence risk by half and 
breast cancer death rate by about a sixth [159]. In patients with a very low risk of local 
recurrence, radiotherapy may be omitted. There is since 2005 an ongoing Swedish national 
study (“Strålkohortstudien”), evaluating the omission of radiotherapy after BCS in a cohort of 
patients older than 65 years with small tumors [9]. Also in DCIS, long-term follow-up show 
that radiotherapy after BCS approximately halves the local recurrence risk [160-163]. 
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However, the survival benefit is minimal since survival in DCIS is comparable to the 
background population [164]. In the updated meta-analysis by EBCTCG from 2014, it is 
concluded that radiotherapy reduces both locoregional recurrence rates and breast cancer 
mortality also in women having modified radical mastectomy and 1-3 positive lymph nodes 
[165]. Swedish National Guidelines recommend locoregional radiotherapy in this scenario 
but do not routinely include the internal mammary lymph nodes [18]. However, a large 
multicenter trial randomly assigned patients with node-negative medially or centrally located 
breast cancers or node-positive laterally located breast cancers, to regional nodal irradiation 
including internal mammary and medial supraclavicular lymp nodes or not, and reported after 
median 10 years of follow-up improved DFS and distant DFS although overall survival was 
not significantly improved [166]. 
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3 AIMS OF THE THESIS 
_________________________________________________________________________ 
The overall aim of this thesis was to investigate sentinel lymph node biopsy (SLNB) and its 
current role in breast cancer treatment in with a focus on current controversies and limitations 
within different clinical settings and to examine whether our results have implications on 
future treatment indications. Specifically the aims were as follows:  
3.1 PAPER I 
To investigate the incidence of axillary surgery and node-positivity in patients with pure 
ductal carcinoma in situ according to the final pathology report. The secondary aim was to 
investigate whether additional tumor sectioning would reveal overlooked occult 
microinvasion, possibly obviating the need for SLNB. 
3.2 PAPER II 
To investigate the impact of prior diagnostic excisional surgery on the number and locations 
of sentinel lymph nodes, before compared with after breast surgery, evaluated with hybrid 
SPECT/CT imaging.  
3.3 PAPER III 
To investigate the accuracy and clinical relevance of SLNB performed before neoadjuvant 
systemic therapy (NAST) in clinically node-negative patients with breast cancer within a 
multicenter setting. 
3.4 PAPER IV 
To investigate the feasibility and accuracy of SLNB performed after NAST in clinically 
node-positive patients with breast cancer within a multicenter setting and evaluate whether 
axillary lymph node dissection can be omitted in case of nodal downstaging. 
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4 PATIENTS AND METHODS 
__________________________________________________________________________ 
4.1 PATIENTS 
4.1.1 Paper I 
A retrospective registry study investigating the incidence of SLN metastasis in patients with a 
postoperative diagnosis of pure DCIS (ductal carcinoma in situ). The data source used was 
the web-based Swedish National Breast Cancer Registry (INCA) [9], which combines 
mandatory reporting to the Swedish Cancer Registry [8], with voluntary reporting to the 
Breast Cancer Registry [9]. Double reporting can thus be avoided. Nearly100 % of all newly 
diagnosed breast cancers are reported, and the primary data completion rate was 97% in 
2015. From the registry, all patients primarily operated for a pure DCIS according to the the 
final pathology report in the period January 1, 2008 to December 31, 2009 were retrieved. 
For practical reasons validation of the register was performed in 15% of patients registered in 
the Stockholm area. In these 40 individuals, 13 out of 1160 variable fields were incorrect 
(1.1%). However, in the registered data from outside Stockholm, incongruent data and 
missing values were more common. It was therefore necessary to review the medical records 
and pathology reports for 338 individuals, correcting and validating the extracted data.  
4.1.2 Paper II 
A prospective study evaluating lymph drainage alterations from the breast to the axillary 
lymph nodes after prior diagnostic breast surgery. Patients were eligible for enrollment if they 
were scheduled for unilateral excisional breast surgery or diagnostic BCS for a most likely 
benign tumor. Indications for surgery were growing fibroadenomas, papillomas with or 
without nipple discharge, inconclusive findings after triple assessment and the patient’s own 
choice to remove a benign lump. The surgery was performed at Södersjukhuset between 
December 2010 and December 2014. Exclusion criteria were planned bilateral surgery, 
pregnancy, physical or psychological inability to participate and linguistic difficulties. 
4.1.3 Paper III & IV 
A prospective multicenter trial evaluating the accuracy and clinical relevance of SLNB within 
the neoadjuvant setting. The trial opened in October 2010 and initially there were 17 
recruiting hospitals, but owing to a slow inclusion rate, three more hospitals were invited after 
ethical approval. All patients scheduled for NAST with biopsy-proven invasive breast cancer 
were eligible. Depending on their clinical nodal status at diagnosis, patients were enrolled 
into two different arms of the trial. In the first arm (paper III), clinically node-negative 
patients were prospectively enrolled at thirteen recruiting hospitals. In the second arm (paper 
IV) patients with T1-4d biopsy-proven clinically node-positive breast cancer were enrolled at 
ten recruiting hospitals. The exclusion criteria were allergic reactions to blue dye or 
radioactive tracer and the inability to give informed consent. In paper III, patients with 
 26 
inflammatory breast cancer (IBC) were excluded in addition. The whole trial closed in 
December 2015 after having reached its accrual goal for paper III. 
4.2 METHODS 
4.2.1 Paper I 
A case-control study was performed in choosing two matched SLN-negative individuals for 
each patient with tumor deposits in the SLNs. The matching criteria were nuclear grade, 
tumor extent and closest age. All remaining archived paraffin blocks from the primary tumors 
were retrieved from the 14 corresponding pathology departments after approval from the 
local biobank coordinator. Additional sectioning of the tumor blocks including large sections 
if available, was performed to expand the examined tissue as follows: From the surface of the 
block (level 1) three sections were cut and then the block surface was cut down 150 µm and 
three sections 4-4.5 µm each were saved (level 2). Then the block was cut down an additional 
150 µm and three more sections with the same thickness were again collected (level 3). One 
section from each of the three levels was stained with haematoxylin and eosin and examined 
by a senior pathologist blinded to all tumor and patient information. If microinvasion was 
suspected, IHC staining with myoeptielial markers p63 and calponin was performed on the 
two remaining sections from that same level. Another experienced pathologist confirmed all 
areas with microinvasion. SLN metastasis was classified according to the AJCC staging 
manual. 
4.2.2 Paper II 
One week prior to surgery and approximately six weeks postoperatively, patients were 
examined with planar scintigraphy and SPECT/CT integrated dual head gamma imaging 
camera (Siemens Symbia T16, Erlangen, Germany) with low-energy high-resolution 
collimators. Each breast was injected subcutaneously inferior to the areola with 0.4 ml of 
99m
Technetium labeled nanocolloid. The non-operated breast served as a control evaluating 
reproducibility with SPECT/CT imaging performed repeatedly. Each procedure started with 
planar images with lymphoscintigraphy one hour after injection with the patient in the prone 
projection with her hands up behind the head. The images were reviewed and if no tracer 
uptake was evident on either side, repeated lymphoscintigraphy was performed two hours 
after injection. SPECT/CT imaging was performed whenever a hot sentinel node was 
detected on planar images. SPECT acquisition was performed with 64 projections over an 
angle of 360 º and the projections were reconstructed with Hybrid Recon™ (Hermes Medical 
Solutions). CT images were subsequently taken with the patient in the same position, images 
reconstructed and optimized for soft tissue and with 5 mm slice thickness. SPECT and CT 
images were then fused and reviewed in a Hybrid Viewer™ (Hermes Medical Solutions). 
The whole procedure was repeated six weeks postoperatively. Images were reviewed by an 
experienced breast surgeon and a senior resident in radiology, and the reviewers had no 
knowledge of which breast was the operated one. SPECT/CT images prior to and following 
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surgery were compared in three projections (sagittal, coronal and transaxial). A radioactive 
SLN in the left axilla is visualized with SPECT/CT imaging and displayed in Figure 4.  
 
Figure 4 Hybrid SPECT/CT imaging visualizing a radioactive SLN in the left axilla of a 
study patient (transaxial projection). 
All operated and non-operated breasts were reviewed separately and analyzed. Results were 
classified as follows: 
Total concordance: the same number and locations of SLNs were recorded postoperatively, 
but also further SLNs in addition to those recorded preoperatively were included here. 
Partial concordance: at least one SLN was recorded in the same location postoperatively, but 
an overall lower number of SLNs were recorded. 
Discordance: no SLNs were postoperatively found in the same location as recorded 
preoperatively or there were no visible radioactive SLNs either pre-or postoperatively. 
Breast sides with no visible SLNs neither pre- nor postoperatively were excluded from 
concordance analysis. 
BMI was subdivided into normal weight (18.5-24.9 kg/m
2
), overweight (25.0-29.9 kg/m
2
) 
and obese (30.0 kg/m
2
 and over). The radiological size of the lesion was primarily based on 
mammographical measurements. For lesions not detectable on mammography, the 
sonograhical dimensions were used. 
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4.2.3 Paper III 
All patients in the trial had biopsy-proven invasive breast cancer. Histological grade and type 
including biomarkers were assessed on pre-therapy core biopsy findings. Clinical tumor size 
at diagnosis was based on mammographical measurements, but in a few cases 
mammographical size was not possible to determine and sonographical measurements were 
used instead. Regional lymph nodes were examined with ultrasound and if suspicious lymph 
nodes were encountered, fine needle aspiration cytology (FNAC) was performed. Clinically 
node-negative patients were eligible for this arm of the trial. SLNB was performed before the 
start of NAST. A repeat SLNB after NAST was encouraged but not mandatory. After NAST, 
ALND was performed in all patients together with breast surgery irrespective of the result of 
the SLNB upfront. A flow chart of the trial is presented in Figure 5.  
 
Figure 5 Flow chart of the Swedish multicenter trial evaluating SLNB in NAST.  
SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, NAST neoadjuvanat 
systemic therapy, cN0 clinically node-negative, cN+ clinically node-positive. 
Preoperative lymphoscinitigraphy was optional. Lymphatic mapping was performed with 
99m
Technetium-labeled nanocolloid injected in the breast on the day of surgery or the day 
before. Intraoperatively a handheld gamma probe was used to identify radioactive lymph 
nodes alone or mostly together with Patent Blue V® dye (Guerbet, Paris, France) injected in 
the breast approximately ten minutes before skin incision. A SLN was defined as any blue 
node or node with afferent blue lymphatics, the hottest node and any node with gamma count 
higher than 10% of the hottest node and finally, suspicious nodes on digital exploration. 
Intraoperative SLN analysis was not performed before NAST, but was allowed in repeat 
SLNB after NAST. Both neoadjuvant chemotherapy and endocrine therapy were allowed. 
Standard chemotherapy was given according to regional guidelines or within ongoing study 
protocols. Endocrine therapy consisted of aromatase inhibitors. Anti-HER2 therapy in HER2-
positive patients was either single or double blockage.  
Response evaluation was performed by comparing clinical and radiological findings in breast 
and regional lymph nodes at diagnosis and before definitive surgery with information 
extracted from medical records and pathology reports. Clinical response was evaluated 
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according to UICC criteria [167]. Radiological response was evaluated with mammography 
and or ultrasound and assessed by a breast radiologist according to the Response Evaluation 
Criteria In Solid Tumors (RECIST)-criteria [168]. Pathological response was assessed by a 
breast pathologist, the principal investigator or the local study coordinating breast surgeon 
after reviewing pathology reports. The response was classified according to Sataloff et al 
[169]. The different classifications used for response evaluation are presented in Table 1.  
Table 1 Different classifications used for response evaluation of NAST in papers III and IV. 
 Complete 
response 
Partial 
response 
No change Progress 
Clinical 
response in 
tumor (ycT) 
The disappearance 
of all known disease 
50% or more 
decrease in total 
tumor load 
A 50% decrease in 
total tumor size 
cannot be 
established nor an 
increase of 25% 
25% or more 
increase in size of 
one or more 
measurable lesions 
Radiological 
response in 
tumor (ycT) 
The disappearance 
of all known disease 
30% or more 
decrease in the 
sum of the longest 
diameter in target 
lesions 
A 30% decrease in 
the sum of the 
longest diameter in 
target lesions 
cannot be 
established nor an 
increase of 25% 
25% or more 
increase in the sum 
of the longest 
diameter in target 
lesions 
 Sataloff A Sataloff B Sataloff C Sataloff D 
Pathological 
response in 
tumor (ypT) 
Total or near total 
therapeutic effect (T-
A) 
>50% therapeutic 
effect but less 
than total or near 
total (T-B) 
<50% therapeutic 
effect, but effect 
evident (T-C) 
No therapeutic 
effect (T-D) 
Pathological 
response in 
nodes (ypN) 
Evidence of 
therapeutic effect, no 
metastatic disease 
(N-A) 
No nodal 
metastasis or 
therapeutic effect 
(N-B) 
Evidence of 
therapeutic effect 
but nodal 
metastasis still 
present (N-C) 
Viable metastatic 
disease, no 
therapeutic effect 
(N-D) 
 
 
Breast surgery was either BCS or mastectomy. Axillary lymph node dissection levels I and II 
was performed in all patients.  
The histopathological examination was according to national guidelines as stated in the 
KVAST document [170]. All SLNs were fixed in formalin and sliced at 2 mm intervals and 
embedded in paraffin. Each paraffin block was then serial sectioned at three 200 µm levels 
and each level stained with haematoxylin and eosin. IHC staining with cytokeratin was not 
mandatory but was recommended if no tumor deposits were detected at that level. Non-SLNs 
were also handled according to national guidelines. Postoperative stage classification 
(ypTNM) and SLN metastasis classifications were based on the 7
th
 edition of the AJCC 
staging manual. No residual invasive cancer but residual in situ carcinoma was considered 
pathological complete response (ypT0/is) [171]. The presence of isolated tumor cells 
ypN0(i+), was not defined as nodal pCR [21] . 
True-negative: patients with negative SLNs and negative non-SLNs.  
True-positive: patients with positive SLNs and positive or negative non-SLNs. 
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False-negative: patients with negative SLNs and at least one positive non-SLN.  
Identification rate (IR): the number of patients with a successfully identified SLN divided by 
the number of patients in whom an SLNB was attempted.  
False negative rate (FNR): The proportion of patients with a false-negative SLN before 
NAST divided by all node-positive patients. In SLNB after NAST, FNR was defined as the 
proportion of patients with a false-negative SLN after NAST divided by all patients with an 
identified SLN after NAST and at least one positive axillary lymph node after NAST. 
Accuracy: the proportion of patients with a true-positive or true-negative SLN out of all 
patients with successfully identified SLNs. 
Sensitivity: the proportion of patients with a positive SLN out of all node-positive patients. 
Specificity: the proportion of patients with a negative SLN out of all patients with only 
negative lymph nodes.  
Positive predictive value: the probability that patients with positive SLNs have positive non-
SLNs. 
Negative predicitive value: the probability that patients with negative SLNs have negative 
non-SLNs. 
4.2.4 Paper IV 
In paper IV similar methods as outlined for paper III were utilized but with a set of 
amendments. In the second arm of the trial, patients with T1-4d stage breast cancer planned 
for NAST with biopsy-proven node positive disease were eligible. SLNB was attempted in all 
patients after NAST together with a mandatory ALND. Clinical node negativity after NAST 
was not a requirement for SLNB to be attempted. The magnetic tracer SPIO was allowed 
alone or in combination with blue dye or radioactive tracer. Intraoperative analysis of SLNs 
after NAST was allowed but was not mandatory. The trial is registered with the identifier 
NCT02031042 at clinical.trials.gov. 
4.3 STATISTICAL ANALYSIS 
4.3.1 Paper I 
Factors affecting the decision to perform SLNB were analyzed by a univariable logistic 
regression model for each independent factor separately followed by a multivariable logistic 
regression model. Results were given as odds ratios (OR) with corresponding 95% 
confidence intervals (CI). Only variables known preoperatively were entered in the regression 
analysis. Univariable and multivariable logisitic regression analyses were also performed 
with SLN metastasis (N1 according to TNM classification) as the dependent variable. The 
agreement of clinical estimates of tumor size in case of a palpable tumor, to final pathological 
tumor size was assessed using Cohen’s kappa. The ĸ value corresponds with poor <0.00, 
slight 0.00-0.20, fair 0.21-0.40, moderate 0.41-0.6, substantial 0.61-0.80 and almost perfect 
>0.80 agreement. The variable hospital volume, was subdivided after visual binning into low 
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(≤ 10 SLNB procedures per year), intermediate (11-29 procedures) and high volume (≥30 
procedures). P<0.05 was considered statistically significant. The statistical software IBM 
SPSS Statistics Version 21.0 (Armonk, NY; USA) was used for all analyses. 
4.3.2 Paper II 
The comparison of groups according to SLN concordance in operated breasts, SLN 
visualization per procedure and the distribution of non-visualisation between operated and 
non-operated procedures was performed after exploring the data distribution. For comparison 
of non-parametric continuous data, the Mann-Whitney U test was applied, for non-parametric 
categorical data, Pearson’s Chi-tests were applied and Fisher’s exact test was used for low 
case numbers. For the comparison of parametric continuous data, the independent two 
samples t-test using equal variance was used. P<0.05 was considered statistically significant. 
IBM SPSS Statistics Version 22.0 (Armonk, NY, USA) was used for all analyses. 
4.3.3 Paper III & IV 
A sample size calculation was performed prior to initiation of the trial for paper III only, 
since the aim of paper III was primary aim for the wole trial. With an estimated 50% of all 
clinically node-negative patients having a positive SLNB, and a proposed sample size of 200 
patients, estimation of the FNR in SLNB before NAST was based on 100 patients. If 
assuming a true FNR in the population of 8%, a power of 80% will be achieved with reported 
confidence intervals (CI) of +/- 7 percentages. Comparison of false-negative to true-positive 
and true-negative SLNs before (paper III) or after (paper IV) NAST was performed after 
exploring the data distribution. For comparison of non-parametric continuous data the Mann-
Whitney U test was used and for non-parametric categorical data, the Fisher’s exact test was 
used. A p-value of <0.05 was considered statistically significant. The statistical software 
program IBM SPSS Statistics for Windows Version 23.0 (Armonk, NY, USA) was used for 
all analyses.  
4.4 ETHICAL CONSIDERATIONS 
4.4.1 Paper I 
This was a registry study so consent from the study participants was not necessary. Ethical 
permission for review of medical records and pathology reports to complement and correct 
incongruent data, as well as permission for additional sectioning of tumor tissue blocks, was 
sought and approved. Two patients of the matched cases in which the additional sectioning of 
the tumor blocks revealed occult microinvasion, were not aware that their tumor tissue blocks 
were reviewed and we decided not to inform them, since several years had passed since their 
primary surgery and change in therapy was not relevant. 
4.4.2 Paper II 
Written informed consent was obtained from all study subjects. Due to slow accrual, patients 
were eventually paid to cover loss of income due to absence from work for each of the two 
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SPECT/CT imaging procedures, which took a couple of hours in time each to complete. 
Before each imaging procedure, an amount of 30 MBq radioactive nanocolloid was injected 
in each breast below the areola. The total radiation dose for both procedures including 
SPECT/CT imaging was estimated to 4.6 mSv, which is equivalent to four years of 
background radiation. Approval from both the Regional Ethics Committee at Stockholm 
County and the Radiation Protection Committee at Karolinska University Hospital Huddinge 
was attained. 
4.4.3 Paper III & IV 
All study subjects were prospectively enrolled and informed about the trial. Written informed 
consent was mandatory before trial eligibility. SLNBs were performed before NAST in paper 
III and consequently an extra surgical intervention was needed with risk of delaying the start 
of NAST. However, the benefit was that half of the patients were informed of negative SLNs 
within a couple of weeks. This information would otherwise not have been available until 
after definitive surgery. Additionally, axillary radiotherapy could be omitted in patients with 
negative SLNs upfront. On the other hand, those being both clinically and pathologically 
node-negative at diagnosis with operable breast tumors, could have been spared the morbidity 
of the mandatory ALND, if primary surgery would have been performed instead. However, 
there are other advantages with NAST as previously mentioned, which also applied to the 
study subjects. 
In paper III SLNB was performed both before and in some patients repeatedly after NAST. 
Lymphatic mapping was performed on both occasions with radiolabeled nanocolloid injected 
into the breast together with Patent Blue V dye in most patients. The radiation dose 
associated with each procedure was 40 MBq, if injected the same day, or the double the 
amount if administered the day before. The radiation exposure from each injection was less 
than 1 mSv, approximately equivalent to one year of background radiation. According to the 
literature, the radiation exposure associated with SLNB is minimal [100]. The blue dye used 
in the trial, was injected after the patient was anaesthetized, thereby avoiding the pain from 
the injection. In addition the patient was securely supervised, which is important since the 
blue dye can cause anaphylactic reactions in 0.5-1% of patients [97]. Especially if BCS is 
performed, a blue discoloration in the skin can be left in place for months, but eventually 
disappears. In paper IV, a few patients were mapped with the magnetic tracer SPIO, which 
can leave a brown discoloration in the skin. This discoloration may still be present after 15 
months in approximately 8% of patients according to Karakatsanis et al [172]. 
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5 RESULTS 
__________________________________________________________________________ 
5.1 PAPER I 
Initially, 1325 patients with a postoperative diagnosis of pure DCIS were identified, but after 
review of selected medical records and pathology reports, 52 patients were excluded leaving 
1273 patients for the final analysis. A flow chart is displayed in Figure 6. 
 
Figure 6 Flow chart for the exclusion of cases in paper I. 
DCIS ductal carcinoma in situ, LCIS lobular carcinoma in situ, ADH atypical ductal 
hyperplasia. 
The median age of the patients was 60 years (range 26-92). Preoperative tumor size estimated 
clinically was in agreement with the postoperative histopathological report in 60.1% 
(196/326) of cases with palpable tumors (ĸ=0.33). Clinicopathological characteristics, 
including hospital volume are displayed in Table 2. SLNB was performed in 59.2% 
(753/1273) of patients. In addition, axillary sampling was performed in five and ALND in 19 
patients without tumor deposits in the retrieved lymph nodes, thus 61.0% (777/1273) had 
some kind of axillary surgery. Five out of 753 (0.7%) patients with SLNB performed, had 
SLN metastasis (pN1 or pN1mi). Three of these five patients also had ALND with no 
additional non-SLN metastases found. In addition, six patients had isolated tumor cells in the 
SLNs (pN0(i+)). Further details on the eleven patients with tumor deposits in their SLNs are 
displayed in Table 3.  
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Table 2 Main characterisitics of the study population in paper I. 
 
 
No. of patients* 
(n=1273) 
  
Hospital volume  
 Low  
 Intermediate 
 High volume  
214 (16.8) 
772 (60.6) 
287 (22.5) 
Age (years)  
 Median (range) 
 ≤50 
 51-70 
 ≥70 
60 (26-92) 
297 (23.3) 
766 (60.2) 
210 (16.5) 
Final breast surgery  
 BCS 
 Mastectomy 
 Unknown 
762 (59.9) 
509 (40.0) 
2 (0.2) 
Multidisciplinary conference  
 No  
 Yes 
 Unknown 
149 (11.7) 
1089 ( 85.5) 
35 (2.7) 
Method of diagnosis  
 Histopathological 715 (56.1) 
  Cytological 
 Unknown 
501 (39.3) 
57 (4.5) 
DCIS size pathological (mm)  
 Median (range) 
 ≤20 
 21-50 
 ≥51  
 Unknown 
20 (1-150) 
671 (52.7) 
413 (32.4) 
139 (10.9) 
50 (3.9) 
Nuclear grade  
 1 158 (12.4) 
 2 384 (30.1) 
 3 
 Unknown 
513 (40.3) 
218 (17.1) 
*With percentages in parentheses unless indicated otherwise.  
DCIS ductal carcinoma in situ, BCS breast-conserving surgery. 
 
Additional tumor sections were reviewed in the eleven patients with tumor deposits in the 
SLNs and in 21 of 22 matched controls with available tumor blocks. A median of 8 blocks 
were available per patient (range 1-21). In one out of 11 women (9%) with SLN tumor 
deposits, and in two out of 21 matched control patients without tumor deposits, occult tumor 
invasion was found. 
In univariable and multivariable logistic regression analysis, none of the examined variables 
age, screening-detected, palpability, method of detection, histopathological tumor size or 
nuclear grade, were significantly associated with SLN metastasis. Predictors of SLN 
metastasis are displayed in Table 4. 
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Table 3 Characteristics of the 11 patients with pure DCIS and SLN tumor deposits. 
Pat
no. 
Final  
breast 
surgery 
Tumor  
extent 
(mm) 
Nuclear  
grade 
SLN 
met 
Number 
of SLNs 
Axillary 
met 
(number) 
Axillary  
lymph 
nodes 
(number)  
Final 
axillary 
staging 
procedure 
58 BCS 18 3 pN1 1 1 13  clearance 
50 mastectomy . 3 pN1 3 1 13 clearance 
80 mastectomy 50 3 pN1mi 3 1 5 sampling 
53 mastectomy 50 3 pN1mi 2 1 15 clearance 
70 mastectomy 35 2 pN1mi 2 1 2 SLNB 
61 mastectomy 50 2 pN0(i+) 2 0 3 SLNB 
54 mastectomy 40 3 pN0(i+) 1 0 1 SLNB 
54 mastectomy 50 3 pN0(i+) 1 0 6 clearance 
44 mastectomy 40 3 pN0(i+) 3 0 7 sampling 
42 BCS 12 3 pN0(i+) 2 0 5 sampling 
33 mastectomy 55 2 pN0(i+) 3 0 3 SLNB 
pN1: macrometastasis >2 mm, pN1mi: micrometastasis >0.2 but ≤ 2mm, pN0(i+): isolated 
tumor cells ≤0.2 mm, BCS breast-conserving surgery, SLN sentinel lymph node, SLNB 
sentinel lymph node biopsy, DCIS ductal carcinoma in situ 
 
 
Table 4 Predictors of SLN metastasis in pure DCIS. 
OR odds ratio, CI 95% confidence interval, SLN sentinel lymph node, pT1 tumor size1≤20 
mm, pT2 tumor size 21-50 mm, pT3 tumor size>50 mm. 
Predictors of SLN 
metastasis N1 
Univariable  Multivariable  
OR CI P-value OR CI P-value 
       
Age       
 ≤ 50 yrs ref      
 51-70 yrs 1.25 0.13-12.10 0.847   0.996 
 ≥71 yrs 1.86 0.11-30.10 0.661   1.000 
Screening-detected       
 No ref      
 Yes 0.27 0.05-1.62 0.152 0.61 0.05-7.36 0.698 
Palpable tumor       
 No ref      
 Yes   0.993   0.993 
Method of diagnosis       
 Histopathological ref      
 Cytological    0.994   0.994 
Pathological T size       
 pT1 ref      
 pT2 3.35 0.35-32.36 0.297 1.86 0.15-22.85 0.627 
 pT3 0.00  0.997   0.997 
Nuclear grade       
 Grade 1 ref      
 Grade 2   0.998   0.997 
 Grade 3   0.998   0.997 
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Table 5 Predictors of SLNB in preoperatively diagnosed DCIS. 
 Univariable  Multivariable   
Predictors of SLNB OR CI P-value OR CI P-value 
       
Hospital volume       
 Low ref      
 Intermediate 1.33 0.98-1.80 0.067 1.10 0.70-1.70 0.698 
 High 1.60 1.12-2.30 0.010* 0.94 0.56-1.57 0.806 
Age       
 ≤ 50 yrs Ref      
 51-70 yrs 0.83 0.63-1.10 0.188 0.71 0.48-1.06 0.094 
 ≥71 yrs 0.53 0.37-0.77 0.001** 0.43 0.25-0.72 0.001** 
Type of breast surgery      
 BCS Ref      
 Mastectomy 4.25 3.29-5.49 0.000** 4.26 2.99-6.07 0.000** 
Multidisciplinary conference      
 No  Ref      
 Yes 1.47 1.04-2.07 0.029* 1.57 0.97-2.53 0.066 
Screening-detected       
 No ref      
 Yes 1.52 1.20-1.93 0.001** 2.37 1.58-3.54 0.000** 
Method of diagnosis      
 Histopathological 
diagnosis 
ref      
 Cytological 
 diagnosis 
3.875 2,99-5.01 0.000** 5.30 3.74-7.50 0.000** 
Palpable tumor      
 Not palpable ref      
 cT1 2.23 1.62-3.10 0.000** 2.54 1.62-3.98  0.000** 
 cT2 3.86 2.24-6.63 0.000** 2.67 1.36-5.213 0.004** 
 cT3 5.68 1.97-16.41 0.001** 2.97 0.80-11.01 0.103 
* p< 0.05, ** p< 0.01. OR odds ratio, CI 95% confidence interval, BCS breast-conserving 
surgery.  cT1≤20 mm, cT2 21-50 mm, cT3>50 mm. 
 
On univariable logistic regression analysis, factors significantly associated with the decision 
to perform SLNB were hospital volume, age, type of breast surgery, discussion at a 
multidisciplinary cancer conference, detection by screening, method of diagnosis and 
preoperatively assessed clinical tumor size.  
On multivariable logistic regression analysis, the following factors remained significantly 
associated with the decision to perform SLNB: age, type of breast surgery, detection by 
screening, method of diagnosis and tumor size assessed clinically.  
Women having mastectomy, a screening-detected tumor, a preoperative diagnosis based on 
cytology and a palpable tumor, were significantly more likely of having SLNB whereas 
women aged 71 years and above were significantly less likely of having undergone SLNB. 
Predictors of SLNB performed in preoperatively diagnosed DCIS are presented in Table 5. 
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5.2 PAPER II 
The 37 patients in the final analysis were examined between September 2011 and January 
2015. The first eleven prospectively evaluated patients were excluded for technical reasons. 
CT imaging was performed with 5 mm slice thickness which caused too much image noise 
and in almost half of the patients, radioactive lymph nodes could not be visualized in at least 
one procedure. The following 37 patients were instead examined with 0.75 mm slice 
thickness and with attenuation correction which improved the image quality markedly. A 
flow chart over the study subjects is presented in Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Flow chart of study subjects in paper II. 
The median age of the 37 patients was 56 years (range 16-73), the median excised breast 
volume was 36.5 cm
3 
(range 3-330) and the median weight of excised breast tissue was 22 g 
(range 1.5-172). This information was, however, missing in nine individuals. A SLN was 
visualized in 93.2% (138/148) of all procedures overall and in 91.9% (34/37) of postoperative 
procedures on operated sides to be compared with 93.7% (104/111; p=0.771) of all 
procedures on non-operated sides, including preoperative procedures on the operated side. 
Total or partial concordance was observed in 85.7% (30/35) on operated and 88.9% (32/36; 
p=0.735) on non-operated sides. None of the studied clinical and pathological characteristics 
differed significantly between discordant and concordant operated breast sides. Clinical and 
pathological characteristics on operated sides of the 35 evaluable patients are displayed in 
Table 6.  
Prospectively enrolled  
n=64 individuals 
Excluded n=16 
planned bilateral operation (n=1) 
logistical reasons (n=3) 
withdrawn consent before second examination 
(n=9) 
higher than intended radiation dose at first 
examination (n=1) 
technical reasons (n=1) 
malignant findings on the final pathological 
examination needing reoperation (n=1) 
Available for final evaluation 
n=48 individuals 
Excluded n=11 
5 mm CT thickness according to study protocol 
Final analysis  
n=37 individuals  
148 imaging procedures 
 
(both breast sides, pre- and 
postoperatively=37x4=148) 
Excluded from concordance analysis 
Two operated breasts (37-2=35) and one non-
operated breast (37-1=36) were excluded due to 
no visible sentinel nodes neither pre- nor 
postoperatively 
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Table 6 Clinical and pathological characteristics according to SLN concordance analysis in 
operated breast sides.  
Values in parentheses are percentages unless indicated otherwise. 
P< 0.05 was considered statistically significant.  
a
Non-parametric continuous data= Mann-Whitney U test 
b
Non-parametric categorical data= Pearsons Chi-square test 
c
 Parametric continuous data= Independent samples t-test (equal variance) 
SLN sentinel lymph node, BMI Body Mass Index. 
 
 
 Partial or total 
concordance (n=30) 
Discordance 
(n=5) 
 
P 
    
Age (years)    
 Median  
 Range 
50 
16-72 
61 
39-73 
 
0.697
a 
BMI class    
 Normal weight 
 Overweight 
 Obese 
21(70.0) 
6(20.0) 
3(10.0) 
3(60.0) 
1(20.0) 
1(20.0) 
 
 
0.804
b 
Radiological lesion size (mm)    
 Median 
 Range 
12 
5-55 
26 
5-40 
 
0.491
a 
Length of skin incision (mm)    
 Median 
 Range 
40 
15-55 
52 
25-60 
 
0.142
c 
Distance from nipple (mm)    
 Median 
 Range 
33 
0-100 
40 
0-68 
 
0.778
c 
Operated quadrant    
 Upper outer 
 Upper inner 
 Lower outer  
 Lower inner 
 Central 
11(36.7) 
3(10.0) 
9(30.0) 
6(20.0) 
1(3.3) 
1(20.0) 
3(60.0) 
1(20.0) 
0(0.0) 
0(0.0) 
 
 
 
 
0.095
b 
Weight of excised tissue (g)    
 Median 
 Range 
23 
2.7-172 
14.3 
1.5-69 
 
0.727
a 
Excised breast volume (cm
3
)    
 Median 
 Range 
36.5 
3.5-330 
49.5 
3-180 
 
1.000
a 
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5.3 PAPER III 
Of 264 eligible patients, 40 withdrew or were excluded for different reasons, leaving 224 
patients from 13 recruiting hospitals in the final analysis. A CONSORT diagram over both 
trial is displayed in Figure 8. 
 
 
Figure 8 CONSORT diagram over the two trial arms in paper III (blue) and IV (red).  
cN0 clinically node-negative, cN1 clinically node-positive,NAST neaodjuvant systemic 
therapy, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, US 
ultrasound, FNAC fine needle aspiration cytology. 
 
The proportion of patients recruited from each site is displayed in Figure 9. Median age in 
paper III was 47 years (range 22-78) and median radiological tumor size at diagnosis was 39 
mm (range 9-127). For clinicopathologic and treatment characteristics for both trial arms, see 
Table 7. 
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Figure 9 Recruiting hospitals for papers III (blue) and IV (red) respectively. 
 
Lymphatic mapping was performed with radiolabeled colloid and Patent Blue V dye (dual 
mapping) in 95.5% (213/223) of patients. At least one SLN was identified in all patients 
before NAST leading to an IR of 100% (224/224). The median number of retrived SLNs 
was two (range 1-11). Half of all patients had a positive SLNB (112/224). The median 
number of macrometastases was 1 (range 1-6). Almost 77% (86/112) of patients with a 
positive SLNB had only negative lymph nodes after NAST, including two patients with 
ITC, ypN0(i+). Nine patients had a negative SLNB before NAST but at least one positive 
lymph node after NAST, resulting in a FNR of 7.4% (95% CI 4.0-13.5) and an accuracy of 
96.0% (215/224). For crosstabulation of SLNB results before NAST and corresponding 
axillary lymph nodes after NAST, see Table 8. The maximum number of positive lymph 
nodes was two. There was no significant difference between patients with a false-negative 
compared with a true-positive or true-negative SLNB regarding the factors listed in Table 
7. The proportion of patients with best clinical or radiological tumor response was 22.2% 
(2/9) and the best pathologic tumor response 11.1% (1/9) among patients with a false-
negative SLNB. The corresponding figures for patients with a true-positive or true-negative 
SLNB upfront were 42.3% (91/215, p=0.089) and 30.7% (66/215, p=0.036) respectively.  
Repeat SLNB after NAST was attempted in 98 patients and dual mapping performed in 
86.7% (85/98). In 68 (69.4%) patients at least one SLN was identified. The median number 
of repeat SLNs was 1 (range 1-5). The FNR for repeat SLNB was 25.0% (3/12). 
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Table 7 Clinicopathologic and treatment characteristics of the whole trial population. 
 paper III (%)  paper IV (%) 
No. of patients 224 195 
Median age, years  47, range 22-78 50, range 27-84 
Radiological T stage   
 T1  18 (8.0) 25 (12.8) 
 T2  149 (66.5) 94 (48.2) 
 T3  57 (25.4) 61 (31.3) 
 T4d (inflammatory) 0 (0.0) 15 (7.7) 
Histological type   
 Ductal 181 (81.5) 158 (83.6) 
 Lobular 28 (12.6) 14 (7.4) 
 Other 13 (5.9) 17 (9.0) 
 Unknown  2 (0.9) 6 (3.1) 
Nottingham histological grade    
 I 5 (3.1) 1 (0.7) 
 II 76 (46.9) 79 (55.6) 
 III 81 (50.0) 62 (43.7) 
 Unknown 62 (27.7) 53 (27.2) 
ER positive 137 (61.2) 134 (68.7) 
   
PR positive 102 (45.5) 95 (48.7) 
   
HER2 positive 72 (32.3) 62 (31.8) 
 Unknown 1 (0.4)  
Neoadjuvant therapy   
 Anthracycline plus taxane 199 (88.8) 184 (94.4) 
 Anthracycline only 10 (4.5) 7 (3.6) 
 Other type 13 (5.8) 3 (1.5) 
 Aromatase inhibitor 2 (0.9) 1 (0.5) 
Anti-HER2 therapy 68(94.4) 58 (93.5) 
   
Breast-conserving surgery 65 (29.0) 51 (26.2) 
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal  
growth factor receptor 2  
 
Table 8 Crosstabulation of SLN status before NAST and overall axillary nodal status. 
 Overall axillary nodal status
a
   
SLNB before NAST Positive Negative Total 
 Positive 112 0 112 
 Negative 9 103 112 
 Total 121 103 224 
a
Lymph node status in SLNs before, SLNs after NAST if performed, and non-SLNs after 
NAST.  
Sensitivity 92.6% (112/121), specificity 100.0% (103/103) and accuracy 96.0 % (215/224). 
SLN sentinel lymph node, SLNB sentinel lymph node biopsy, NAST neoadjuvant systemic 
therapy 
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5.4 PAPER IV 
Of 205 eligible clinically node-positive patients, 195 patients from ten hospitals were in the 
final analysis. A flow chart for both trial arms is presented in Figure 5. All patients had 
cytologically confirmed node-positive disease at diagnosis. The median age was 50 years 
(range 27-84) and the median radiological tumor size was 40 mm (range 11-60). Fifteen 
patients had inflammatory breast cancer (IBC). Clinicopathological and treatment 
characteristics are presented in Table 7. Lymphatic mapping was performed with radiolabeled 
nanocolloid and Patent Blue V dye in 87.5% (168/192) of patients. In 3.6% (7/192) magnetic 
tracer alone or in combination with blue dye was used. Overall IR was 77.9% (152/195) and 
with dual mapping regardless of method, IR improved to 80.7% (138/171). After excluding 
patients with IBC, IR improved slightly to 79.4% (143/180) and with dual mapping IR 
improved somewhat further to 82.8% (130/157). The median number of retrieved SLNs was 
two (range 1-5). SLNB was positive after NAST in 52.0% (79/152) and at least one 
macrometastasis was found in 88.6% (70/79) of patients, with a median of one (range 1-4). 
The median number of non-SLNs was 11 (range 3-41) and 52 out of 79 (65.8%) patients with 
a positive SLNB had additional positive non-SLNs. Of all 195 patients, 124 (63.6%) had 
residual nodal disease after NAST.  
SLNB was negative after NAST in 73 (48%) of 152 patients. Thirteen of them had positive 
non-SLNs for an overall FNR of 14.1% (13/92). A comparison of lymph node status in SLNs 
and non-SLNs after NAST is presented in Table 9.  
Table 9 Comparison of lymph node status in SLNs and overall axillary lymph node status 
after NAST.  
 Overall axillary nodal status (SLNB and ALND) 
SLNB Positive Negative Total 
Positive 79 0 79 
Negative 13 60 73 
Total 92 60 152 
Sensitivity 85.9% (79/92), specificity 100.0% (60/60), positive predictive value 100.0% 
(79/79), negative predictive value 82.2% (60/73).  
SLN sentinel lymph node, SLNB sentinel lymph node biopsy, NAST neaodjuvant systemic 
therapy, ALND axillary lymph node dissection. 
 
Among the false-negative patients the median number of positive lymph nodes was one 
(range 1-9) and the median number of axillary lymph nodes including SLNs was 12 (range 5-
20). Among the false-negative cases there were two patients with IBC and three patients with 
isolated tumor cells (ITC) in their SLNs. FNR calculated for different clinical scenarios are 
presented in Table 10.  
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There was no difference between patients with a false-negative compared with a true-positive 
or true-negative SLNB in relation to the factors displayed in Table 7 or in clinical or 
radiological response to NAST in neither tumor nor lymph nodes. However, there were 
significantly fewer patients with a complete or near complete (Sataloff A) pathologic 
response in the tumor (7.7%) and lymph nodes (0%) in the false-negative group. This was 
compared with the true-positive or true-negative group in which the corresponding figures 
were (35.3%, p=0.044) and (27.3%, P=0.01) respectively. 
Table 10 False-negative SLN rates calculated for different clinical scenarios. 
 
Scenario 
True-pos 
(n) 
False-neg 
(n) 
FNR
a
  
(%) 
Overall  79 13 14.1 
Dual mapping performed 71 11 13.4 
IBC excluded (n=15) 76 11 12.6 
ITC considered ypN+ 87 10 10.3 
SLNB with 1 node retrieved 31 11 26.2 
SLNB with ≥ 2 nodes 48 2 4.0 
SLNB with ≥ 3 nodes 23 0 0.0 
a
Calculated as the number of patients with a false-negative SLN in each scenario, divided by 
the number of false-negative and true-positive SLNs in the same scenario.  
NAST neoadjuvant systemic therapy, FNR false negative rate, SLN sentinel lymph node, 
SLNB sentinel lymph node biopsy, IBC inflammatory breast cancer, ITC isolated tumor 
cells, SLN sentinel lymph node, SLNB sentinel lymph node biopsy, FNR false negative rate. 
 
 45 
6 DISCUSSION 
_________________________________________________________________________ 
6.1 PAPER I 
The incidence of DCIS has increased since the introduction of mammography screening and 
accounts for about 10% of all newly diagnosed breast cancers[9]. DCIS is a pre-invasive 
condition where cancer cells grow in the mammary ducts but respect the basal membrane and 
thus are not able to metastasize. However, SLN metastasis is found in 5-13% [130] of 
preoperatively and 0-4% [173, 174] in postoperatively diagnosed pure DCIS. The 
discrepancy is due to upgrading to microinvasive or invasive breast cancer on definitive 
pathology reports [174, 175]. The rationale for SLNB in larger DCIS is to compensate for 
sampling limitations, so that adjuvant treatment decisions are based on correct TNM staging. 
According to the Swedish National Guidelines valid in 2007, when this study was planned, 
SLNB should be considered in case of a clincial or radiological tumor extent larger than 2 cm 
and high nuclear grade on preoperative core biopsy or high grade atypia on FNAC.  
The primary aim with this study was to investigate the national incidence of SLN metastasis 
in pure DCIS based on the final pathology report. The secondary aim was to examine whether 
a more thorough examination of the tumor blocks could substitute for SLNB. Our hypothesis 
was that SLNB was performed too liberally and also in cases that did not fulfill the National 
Guidelines criteria. Interestingly, according to the registered data for patients having BCS, 
SLNB was performed in three out of four cases despite the criteria from the guidelines not 
being fulfilled. During the same period, the corresponding figure for patients having a 
mastectomy was one out of two cases. In our study, only 0.7% of patients with a 
postoperative diagnosis of pure DCIS and combined with the performance of a SLNB 
developed SLN metastasis. None of the SLN-positive patients had more than one metastasis 
and there were no patients with non-SLN metastases. A Dutch review of 21 studies reported 
an average incidence of 4% for SLN metastasis in postoperatively diagnosed pure DCIS 
[175]. However, the range was wide (0-18%), possibly representing differences in tissue 
sampling techniques and the proportion of large samples. The more extensively the tumor 
blocks are examined, the greater the chance that occult invasion may be revealed. This is 
supported by the results from our study in which occult invasion indeed was discovered after 
re-evaluation and additional sectioning of the tumor blocks, but was found to the same extent 
in both SLN-negative and SLN-positive patients. However, the procedure is labour-intensive 
and costly and therefore not suitable for most clinical settings.  
We did not find any recognized predictive factor for SLN metastasis that was signficantly 
representative upon regression analysis in our study. This may be due to the small number of 
events involved. However, this in line with the results found by Cox et al and Tan et al [176, 
177]. On the other hand, two out of five patients with SLN metastasis did not fulfil the 
criteria stated in the Swedish National Guidelines valid at the time of surgery.  
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On multivariable logistic regression analysis, total mastectomy, screening-detected tumor, 
preoperative diagnosis made by cytology and palpable tumor were all predictors for choosing 
to perform SLNB. SLNB is difficult to perform after mastectomy, invasiveness is hard to rule 
out with cytology and palpability raises suspicion of invasiveness. These are all logical 
predictors for choosing to perform SLNB. The reason for screening-detected tumor being a 
predictor is more intriguing. It is unusual with clincially-detected DCIS. Those proportionally 
few cases in our data may have been an incidental postoperative finding where preoperative 
suspicion was not raised and thus SLNB not considered. Older women were instead less 
likely to be offered SLNB. Instead primary ALND was performed in 8.7% (10/115) of older 
women with available data compared with 1.7% (8/465) in postmenopausal and 0.5% (1/191) 
in premenopausal women.  
Our results, which were based on validated national data from 55 reporting hospitals with an 
almost 100% coverage in the reporting of new breast cancer cases, found a markedly low 
incidence of SLN metastasis in postoperatively diagnosed pure DCIS. However, some critics 
claim that this information is of little use in preoperative decision-making on whether to 
perform SLNB or not if BCS is planned. On the contrary, since the incidence of SLN 
metastasis was so low, our recommendation, in line with most international guidelines, is to 
postpone nodal staging until the final pathology report is available unless a mastectomy is 
planned.  
6.2 PAPER II 
After triple assessment almost 10% of patients are planned to receive a diagnostic breast 
excision in order to achieve a conclusive diagnosis [9]. Those patients with an invasive form 
of breast cancer, diagnosed after excisional surgery, are more often node-negative compared 
with patients with a conclusive cancer diagnosis prior to surgery. Since SLNB is associated 
with morbidity, although to a lesser extent than ALND [82, 94], SLNB should only be 
performed where there is a clear indication. Therefore, SLNB as a second operation for the 
purpose of nodal staging is preferable. However, earlier results with a secondary SLNB after 
prior diagnostic excisional surgery has been associated with lower IR [133, 178] and higher 
FNR especially in large excisional biopsies [101, 132]. Borgstein et al and Feldman et al both 
used radioactive tracer without blue dye and injected the radioactive tracer into the breast 
tissue surrounding the surgical cavity. Based on these results, SLNB was considered 
inaccurate after prior diagnostic surgery explained by lymph vessel disruption and 
postoperative inflammation, altering lymphatic drainage and redirecting lymph flow so that 
the mapped SLN would not reflect the “true SLN” [133]. In 2007, Celebioglu et al published 
a prospective multicenter study evaluating the safety and accuracy of SLNB after prior 
diagnostic excisional surgery. Dual mapping was applied and the observed IR was 96% and 
the FNR 10% for this group. Although the follow-up was short, the authors concluded that 
SLNB was safe in this setting [137]. This was in line with the results reported by Wong et al 
in 2002, who did not find any statistical difference in IR or FNR compared with patients 
having a needle biopsy performed prior to definitive surgery. The same group also observed 
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that IR was significantly improved if the radioactive tracer was injected dermally instead of 
peritumorally [135]. This observation agrees with the results by McMaster and colleagues 
[179].  
Contrary to these successful results, and the main reason why we decided to perform our 
study, were the findings reported by Estourgie et al, who observed a discrepancy in lymph 
drainage patterns in 17 out of 25 study patients and a discordance in 7 out of 25 (28.0%) 
patients examined with planar lymphoscintigraphy before and after prior excisional surgery 
[180].  
We decided to use hybrid SPECT/CT imaging instead of planar lymphoscintigraphy for the 
comparative imaging studies. With SPECT, three-dimensional, instead of two-dimensional, 
scintigraphic functional images are produced which in combination with precise anatomical 
information from CT, facilitates the comparison and localization of radioactive SLNs [181]. 
The second SPECT/CT procedure was performed approximately six weeks postoperatively. 
This interval was mainly chosen because reoperations for nodal staging often take place after 
six weeks from the initial surgical procedure. Additionally, an interval of more than 36 days 
between the surgical interventions improved detection rates in a recent study by Renaudeau et 
al [182]. This is also supported by high SLN identification rates years after earlier aesthetic 
breast surgery [183, 184].  
For practical reasons we used standardized superficial periareolar injections of the radioactive 
tracer positioned at six o´clock both pre- and postoperatively. The contralateral side was used 
as a control for evaluation of reproducibility with repeat SPECT/CT imaging. To the best of 
our knowledge, repeat SPECT/CT imaging for evaluation of lymph drainage alterations after 
prior diagnostic surgery has not been reported before. Asadi et al used planar 
lymphoscintigraphy to evaluate lymph drainage changes in 18 patients. A comparison was 
performed of lymphatic mapping preoperatively on the day of surgery with the day after an 
excisional biopsy using intra-dermal periareolar injections of radioactive tracer. Apart from 
two patients with non-visualization, the SLNs were in the same location postoperatively 
[185]. Noushi et al later conducted a comparison study of lymph drainage patterns in 39 
patients evaluated with SPECT/CT imaging after sequential subareolar and peritumoral 
injections of radiocolloid with intervals of 2-7 days, without any surgery performed between 
studies. High rates of discordance were found in lymph node mapping to the internal 
mammary and axillary lymph nodes. The conclusion reached was that the location and depth 
of radioactive tracer injection may have implications for both nodal staging and patient 
outcome [186]. In our study there was no statistical difference in concordance (partial or 
total) between operated and non-operated sides, even though concordance was lower on 
operated sides. Similarly, the visualization of SLNs was not significantly different for 
procedures performed postoperatively on operated sides in comparison with procedures on 
non-operated sides or preoperatively on operated sides. Excision volume had no significant 
impact on discordance rates on operated sides. This is in line with the observations made by 
Haigh et al who found that the excision volume did not affect the IR of SLNs [187]. We 
found significantly higher BMI and higher age in procedures with non-visualization, which 
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corroborate with earlier results by Derossis et al who found that BMI was significantly higher 
among patients with failed lymphatic mapping [188]. Lerman et al observed that SPECT/CT 
imaging was superior to planar lymphoscintigraphy in visualizing SLNs in overweight 
patients [189]. Despite only 37 evaluated patients, our results support performing SLNB after 
previous excisional surgery with only a tendency for higher discordance rates on operated 
sides. Larger studies are however welcome to further validate our data. The SLNB technique 
appears to have a margin for error given low recurrence rates [115] and equivalent survival 
[117] after long time follow-up, which is most likely compensated for by modern adjuvant 
therapies.  
6.3 PAPER III & IV 
SLNB is considered gold standard nodal staging procedure in early-stage breast cancer and 
ALND can be safely omitted in case of a negative SLNB [117]. NAST has traditionally been 
offered to patients with locally advanced or inflammatory inoperable stages of the disease and 
ALND is then the traditional nodal staging procedure followed by locoregional radiotherapy. 
However, in the last three decades, the indications for NAST have expanded to also 
encompass patients with operable breast cancer with aggressive tumor biology, rendering 
them candidates for adjuvant chemotherapy [145]. Survival rates are comparable with this 
sequence, and in addition NAST can downsize tumors so that more patients can be candidates 
for BCS after NAST. Chemosensitivity can be evaluated in vivo and treatment adjusted if 
required [146]. Since the proportion of patients with node-positive disease is lower in 
operable breast cancer, and NAST has the potential for nodal conversion in 40-70% of 
patients, SLNB has also been evaluated worldwide in the neoadjuvant setting [155, 190]. 
SLNB before NAST in clinically node-negative patients with breast cancer has been 
evaluated in a number of small single-institution studies. The reported IR is excellent and 
FNR 0% if a complementary ALND was performed in SLNB-negative patients [191-193]. 
However, most studies omitted ALND if SLNB was negative and reported absence of 
recurrences after a median 10-36 months of follow-up [140, 194, 195].  
To the best of our knowledge, our trial is by far the largest in which an ALND was 
performed, irrespective of the result of the SLNB upfront and in addition within a multicenter 
setting. Our patients were recruited from 16 different Swedish hospitals, mostly large-volume 
and university-affiliated. There are still large regional differences in the proportion of patients 
being offered NAST, especially in operable stages of the disease, even though the differences 
are decreasing. Since current guidelines from the National Board of Health and Welfare 
(Socialstyrelsen) recommend NAST to patients with operable aggressive breast cancer stage 
II, the differences will probably decrease further [196]. The IR for SLNB before NAST was 
in paper III 100%, including three patients in whom SLNB was identified only due to a 
suspicious finding upon digital exploration. This high IR agrees with earlier studies 
performing SLNB as part of primary surgery in clinically node-negative patients [101, 197]. 
Dual mapping was performed on 95.5% of patients in our trial. This is known to improve 
detection rates in early-stage breast cancer, especially in a multi-institutional practice [96]. In 
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paper IV, when SLNB was performed after NAST, dual mapping also improved the IR, 
which is in line with the results from both the SENTINA study and the ACOSOG Z1071 trial 
[198, 199]. However, corresponding with the results in the SENTINA study, repeat SLNB 
was associated with low IRs, despite dual mapping in most cases. The reasons for this are 
probably post-surgical tissue scarring and post-NAST inflammatory debris in the lymph 
vessels altering lymphatic drainage [198]. In clinically node-negative patients, SLNB 
performed after NAST is associated with both lower IR and higher FNR compared with 
SLNB performed upfront [141, 200].  
The number of patients with a negative SLNB upfront and at least one positive axillary 
lymph node after NAST was nine for a FNR of 7.4 % (95% CI 4.0-13.5). We did not find any 
significant difference in clinical or treatment characteristics between patients with a false-
negative compared with a true-positive or true-negative SLNB. We do not know if those nine 
“false-negative” patients had additional overlooked positive lymph nodes during primary 
surgery or if they represent metastases that developed during NAST.  
Clinical response to NAST did not differ significantly between patients with a false-negative 
compared with a true-positive and true-negative SLNB, neither for the arm with SLNB 
performed before or after NAST. However, a pathologically complete or near complete 
response in the breast was significantly less frequent among patients with a false-negative 
compared with a true-positive and a true-negative SLNB in both the trial arms. One of the 
patients with a false-negative SLNB before NAST progressed clinically during NAST. 
Pathological response evaluation was graded according to the definitions stated by Sataloff et 
al [169]. Sataloff observed a poor correlation between clinical and pathological response, 
which is in line with our own observations. He further concluded that patients whose tumors 
had the best pathologic response also had the best outcome. Pathological complete response 
(pCR) is an excellent predictor of outcome and the CTNeoBC pooled analysis by Cortazar et 
al shows that pCR correlates with improved survival and that the correlation is strongest for 
patients with aggressive tumor subtypes [148]. The pCR definition recommended by The 
Breast International Group-North American Breast Cancer Group (BIG-NABCG) 
collaboration is no residual invasive carcinoma in the breast and all sampled lymph nodes 
[171]. The latter is important since residual nodal disease impacts negatively on outcome 
even if there is no residual disease in the breast [201, 202]. The BIG-NABCG recommends 
using residual cancer burden (RCB) for the assessment of pathological residual disease [171]. 
RCB is a continuous variable with numerical cut points to define four classes based on 
prospectively sampled data, including: tumor size, cellularity and number and size of the 
largest metastasis. Since the response evaluation in our trial is based on retrospectively 
collected data from pathology reports, we chose to classify pathological response according 
to definitions by Sataloff et al.  
In clinically node-negative patients, SLNB can be performed both before and after NAST 
according to international guidelines [116, 203]. Proponents of performing SLNB after 
NAST argue that only one surgical intervention is needed and that more patients can take 
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advantage of nodal downstaging secondary to NAST and hence be spared ALND if SLNB is 
negative. However, with this sequence, there is uncertainty on upfront nodal stage. 
Ultrasound followed by FNAC has in some studies a sensitivity of only 20-25% in finding 
nodal metastases [75, 76]. If nodal metastases are overlooked upfront and SLNB is false-
negative after NAST in approximately 11% [141, 204] of cases, there is a clear risk of 
locoregional undertreatment. There is a lack of evidence on how to treat the axilla after both a 
negative and a positive SLNB post NAST. Therefore it seems safer to recommend SLNB 
before NAST in clinically node-negative patients at diagnosis pending results from the 
randomized NSABP B-51 and Alliance A011202 trials investigating locoregional treatment 
after NAST [205, 206].  
In paper IV, clinically node-positive patients with cytologically-verified nodal disease were 
eligible. The IR was, as expected, lower compared with earlier results reporting SLNB after 
NAST in clinically node-negative patients, but improved somewhat with dual mapping and 
slightly further after excluding patients with IBC. These results are in line with the IR of 
80.1% in arm C of the four- armed SENTINA study [198]. A low IR in patients with biopsy-
proven nodal disease before NAST is acceptable since the alternative would have been 
ALND. We included IBC in paper IV despite ASCO guidelines recommending against the 
performance of SLNBs in IBC, also after a positive clinical response to NAST [116]. We 
only found two small studies specifically evaluating IBC in the neoadjuvant setting and both 
authors concluded that SLNB was  unsuitable [207], but one of them did not use the dual 
mapping technique [144]. Our results regarding IR and FNR, improved when the cohort of 
IBC patients were excluded, but only marginally and further studies are warranted. 
In clinically node-positive patients, the overall FNR associated with SLNB after NAST is 
unacceptably high [142]. However, if two or more SLNs are retrieved, the FNR decreases, in 
our study to 4%, which agrees with earlier studies [208]. A limitation of our trial was that 
axillary reevaluation after NAST was not performed. The SENTINA study arm C [209] and 
the ACOSOG Z1071 trial both enrolled clinically node-positive patients and reevaluated the 
axilla with ultrasound (AUS) after NAST. In the ACOSOG Z1071trial, fewer patients with 
sonographically normal-looking lymph nodes were node-positive at surgery and the FNR 
based on the AUS findings was lower, although not significantly different [210]. Even though 
the accuracy for AUS in predicting nodal status after NAST is too low, it can be used to 
stratify patients suitable for SLNB with normal-looking lymph nodes and, therefore lower 
risk of false-negative SLNs. Another potential way of lowering the FNR, is to expand the 
definition of a positive node to also encompass ITC. In our trial (paper IV), the FNR 
decreased to 10.3% after having excluded three patients with ITC from the false-negative 
cases. This is in line with Boileau et al in the SN FNAC trial, where the FNR decreased from 
13.3 to 8.4% [211]. In our study, IHC was not mandatory as it was in the SN FNAC study. 
Even minimal residual nodal disease after NAST is thought to be of clinical relevance in the 
neoadjuvant setting, unlike the situation when primary surgery is performed [212]. The 7
th 
edition of the AJCC staging manual recommends including the size of the fibrous stromal 
reaction around the tumor deposit, which in some cases might upgrade ITCs to node-positive 
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disease. Finally, marking the cytologically confirmed nodal metastasis prior to NAST with a 
clip or a radioactive seed and removing that node at definitive surgery together with SLNB, 
also has the potential to lower the FNR as shown in a prospective study by Caudle et al [213]. 
6.4 METHODOLOGICAL CONSIDERATIONS 
To be able to draw conclusions regarding a population based on observations from a sample, 
it is necessary to assess if the conclusions are correct for the people in the study (internal 
validity) and for other groups outside the sample (external validity). 
The internal validity is affected by two types of errors: Random errors and systematic errors. 
Random errors cause unprecise results that differ when you repeat your measurements. 
Random errors can be minimized with a larger study size. In paper III, an a priori power 
analysis was conducted to calculate a sufficient sample size at a power of 80% but with a 
relatively wide CI around the point estimate (FNR), which was accepted since all patients 
was subject to NAST.  
Systematic errors are reproducible inaccuraccies that deviate consistently in the same 
direction causing a lower validity. Selection bias, information bias and confounders are 
different types of common systematic errors. 
Selections bias: In paper II, the two imaging procedures required a couple of hours time each, 
hence employed women were less prone to participate compared with unemployed or retired 
women. Further we chose patients with probably benign tumors as a model for our study to 
avoid reoperation for nodal staging, but we have assumed that there is no major difference in 
lymph drainage pattern compared with a diagnostic excisional biopsy for a postoperatively 
diagnosed breast cancer. In paper III clinically node-negative patients were eligible. These 
women were in most cases enrolled from academic high-volume centres, in which the 
oncologists seemed to be more prone to plan for NAST in operable stages of the disease 
compared with low-volume centres.  
Information bias: In order to avoid information bias in paper I, the two pathologists had no 
information which slide belonged to a patients with tumor deposits in the SLNs or not when 
assessing microinvasion. In paper II the reviwers did not know which breast was the operated 
one when examining the hybrid SPECT/CT images. However, in some cases it was possible 
to decide from the images. In paper III and IV, response was assessed retrospectively with 
information extracted from medical records and pathology reports and thus misclassification 
is possible. In paper IV SLNB was attempted after NAST in conjunction with the mandatory 
ALND, hence there is a possibility that the SLNs were retrieved ex vivo among the harvested 
axillry nodes to save time and thus the IR in reality may be even lower.  
Confounding: In paper I, we choose controls for each case matched for age, tumor extent and 
grade to avoid mixture of effects or confounding. There could still however be additional 
unknown confounders.  
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Type II error: In paper I, we did not find any significant risk factors for SLN metastasis 
which could be due to low case numbers. In paper II, the study size was small and with null 
findings there is a risk for incorrectly having accepted the null hypothesis.  
In paper I the external validity is high since the study is based on national data from the 
Swedish National Breast Cancer Registry, which has high validity and coverage. 
In paper II the internal validity is high, but the results are based on only 37 patients and 
therefore further studies are needed to validate the results. 
Paper III and IV are based on a large prospective national multicenter trial with both low-
volume and high-volume hospitals. In paper III the accrual goal for the number of 
participants was reached and the results can thus be regarded as having a high internal as well 
as external validity. 
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7 CONCLUSIONS 
__________________________________________________________________________ 
 
1. The incidence of SLNB metastasis in postoperatively diagnosed pure DCIS is very 
low and we could not find any significant predictive risk factor for SLN metastasis. 
 
2. In patients with preoperatively diagnosed pure DCIS, SLNB is only indicated if a 
mastectomy is planned or if findings highly suspicious of invasive disease are present. 
 
3. In postoperatively diagnosed pure DCIS, additional tumor sectioning can reveal 
occult microinvasion. However, this finding appears to be equally common in patients 
whether tumor deposits in SLNs are encountered or not, reflecting limitations in tissue 
sampling and the standardized pathological examination of tumor specimens. 
 
4. Prior diagnostic excisional breast biopsy alters the lymphatic drainage pattern from 
the breast to the axillary lymph nodes. However, the magnitude of change was not 
significantly different in operated compared with non-operated breast sides. 
 
5. Our results support the feasibility of SLNB after prior diagnostic breast surgery. 
 
6. SLNB performed before NAST in patients with clinically node-negative breast cancer 
is highly reliable. If SLNB is negative, ALND can be omitted provided good clinical 
tumor response to NAST.  
 
7. SLNB after NAST in patients with clinically node-positive breast cancer is feasible, 
however the IR is lower than in clinically node-negative patients and the FNR 
unacceptably high if only one SLNB is retrieved.  
 
8. Omission of ALND after NAST in clinically node-positive patients upfront, should 
only be considered if two or more SLNs are retrieved. 
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8 FUTURE PERSPECTIVES 
__________________________________________________________________________ 
This thesis has attempted to answer some of the questions surrounding nodal staging and 
specifically the indications and limitations of SLNB in different breast cancer scenarios that 
clinicians are facing today. The surgical therapies available to treat breast cancer have 
evolved from Halsted’s extensive radical disfiguring mastectomy to the current considerably 
less damaging BCS, sometimes incorporating oncoplastic techniques to restore the shape and 
volume of the breast, together with SLNB in clinically node-negative patients. In 
combination with improvements in adjuvant therapy, the survival rates for breast cancer are 
now among the highest compared with other cancer types. Approximately 90% of breast 
cancer patients are alive five years after the initial diagnosis. However, since all surgical 
procedures have side-effects and associated morbidity, the indications must be clear.  
In patients with preoperatively diagnosed DCIS planned for BCS, most current international 
guidelines recommend that SLNB should not be performed unless there is a high suspicion of 
invasive disease [116, 203]. However, SLNB is warranted if mastectomy is planned, as 
performing a secondary SLNB postoperatively is precluded, even though there are reports of 
this having been successfully performed in selected cases [214].  
In addition, after prior excisional breast surgery including BCS, SLNB seems sufficiently 
accurate to be performed as a secondary surgical procedure, in cases where invasive cancer is 
encountered on the final pathology report [215]. 
In recurrent breast cancer, a repeat SLNB has been attempted and seems feasible according to 
a recent meta-analysis, especially if the original axillary surgery was SLNB. However, 
abberant lymphatic drainage patterns visualized on planar lymphoscintigraphy were 
significantly more common if the original axillary surgery had been an ALND [216]. In 
recurrent breast cancer, planar lymphoscintigraphy should probably be routine as aberrant 
drainage pathways and extra-axillary tumor-positive SLNs can be revealed, that may change 
both surgical and adjuvant therapy decisions including radiotherapy plans [217].   
Whether SPECT/CT imaging can be of additional value has been adressed in a recent study 
[218]. However, this can be studied further, including the correlation between time to 
recurrence and its impact on lymphatic regeneration and detection rates. 
In early-stage breast cancer, there is much evidence to support that ALND can be safely 
omitted in case of a negative SLNB without a negative impact on either survival or 
recurrence rates [115, 117].  
The issue is instead how to treat patients with a low tumor burden in the SLNs given current 
adjuvant therapy options. According to international guidelines, ALND can be omitted after 
BCS in clinically node-negative patients if no more than two positive SLNs are present and 
raditohterapy planned [116]. A Swedish-based international randomized trial called 
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SENOMAC (www.senomac.se) with the primary endpoint DFS, is currently enrolling 
patients with maximum two positive SLNs, irrespective of type of breast surgery being 
planned.  
The issue of whether to replace ALND with axillary radiotherapy in case of a positive SLN 
has also been investigated. In the randomized multicenter non-inferiority AMAROS trial, 
both survival and the proportion of axillary recurrences were comparable between groups 
after a median of six years of follow-up but the patients having axillary radiotherapy had 
significantly less arm morbidity in comparison with the ALND group. However, the trial was 
underpowered with very few events [219].  
We have shown that SLNB performed before NAST in clinically node-negative patients is 
highly reliable and complementary ALND can be omitted after NAST in case of good 
clinical response. It is however important to carefully monitor patients in whom ALND is 
omitted with attention to regional recurrences in the future. Patients with a positive SLNB 
upfront can be enrolled into the SENOMAC trial and thus randomized to receive a 
complementary ALND or not, and followed according to the trial protocol. 
SLNB can be attempted on patients who are clinically node-positive at presentation if 
clinically downstaged in the axilla after NAST, according to evaluation with AUS in addition 
to physical examination. However, if only one negative SLNB is mapped a complementary 
ALND should be performed. If two or more negative SLNs are retrieved, ALND may be 
omitted. The question of how best to treat the axilla after NAST is much debated and 
evidence lacking. This issue is under investigation and results pending from two important 
randomized controlled trials, the The NSABP B-51/RTOG 1304 trial evaluating the benefit 
of regional nodal radiotherapy in biopsy-proven node-positive patients with a nodal pCR after 
NAST according to SLNB or ALND and the Alliance A011202 trial, which enrolls patients 
with residual positive lymph nodes after NAST onto ALND with nodal radiotherapy, or no 
ALND but instead nodal and axillary radiotherapy [206].  
In our multicenter trial, the amount of fibrosis in the residual tumor bed and lymph nodes 
after NAST was assessed retrospectively with information from the pathology reports. We 
did not find any significant difference in the amount of fibrosis between false-negative 
compared with true-positive or true-negative SLNs. However, this information was 
unfortunately often lacking or difficult to interpret. It would therefore be interesting to let a 
senoir pathologist centrally reexamine the tissue slides from the tumors and nodes and 
correlate the findings with the outcomes of SLNB. It would also be interesting to sequence 
the genome from the patients’ tumor tissue blocks in order to correlate gene expression 
patterns and molecular subtypes with response to NAST and false-negative rates.  
 
 57 
9 SAMMANFATTNING (SWEDISH SUMMARY) 
__________________________________________________________________________ 
Bröstcancer är kvinnans vanligaste cancerform och varje år insjuknar i Sverige cirka 8000 
kvinnor och 60 män i bröstcancer. Lymfkörtelstatus, det vill säga om bröstcancern har spridit 
sig till de närbelägna lymfkörtelstationerna eller inte, och omfattningen på denna spridnig är 
den viktigaste prognosfaktorn vid bröstcancer. Lymfkörtelstatus har tidigare undersökts med 
lymfkörtelutrymning som innebär att ett drygt tiotal lymfkörtlar opereras bort från armhålan 
dit tumörceller från en bröstcancer oftast sprider sig först.  
På 1990-talet kom portvaktskörtelkirurgi (sentinel node-biopsi) att allt mer ersätta 
lymfkörtelutrymning för stadieindelning. Portvaktskörtelkirurgi innebär att endast den första, 
eller de första, dränerande lymfkörtlarna från bröstet opereras bort. Är den eller dessa 
lymfkörtlar friska, så är de övriga lymfkörtlarna också friska med stor säkerhet och patienten 
slipper lymfkörtelutrymning. Portvaktskörtlarna hittas genom att man sprutar ett radioaktivt 
spårämne i bröstet innan operationen, vanligtvis tillsammans med ett blått färgämne som 
sprutas i bröstet när patienten är sövd. Dessa båda ämnen tas upp och sprider sig i 
lymfbanorna och ansamlas i den eller de första lymfkörtlarna som mottar lymfvätska från 
bröstet. Vid operationen används en liten handhållen gammakamera som riktas mot armhålan 
och som känner av radioaktiviteten i portvaktskörteln och ger ifrån sig ett ljud när man är i 
närheten. Hudsnittet läggs där man får som högst utslag med gamma proben. Vid 
dissektionen följer kirurgen i tillägg till ljudet även de blåfärgade lymfbanorna för att hitta 
portvaktskörtlarna. Fördelen med denna metod är att det kirurgiska ingreppet är betydligt 
skonsammare och att risken för kvarstående besvär från armen i form av känselnedsättning, 
rörelseinskränkning, smärta och armsvullnad minskar. Dessutom så undersöks 
portvaktskörtlarna noggrannare än övriga lymfkörtlar och därmed minskar risken för att 
missa tumörspridning till lymfkörtlarna. Idag är portvaktskörtelkirurgi standard för 
stadieindelning av tidigt upptäckt icke spridd bröstcancer. Det övergripande syftet med denna 
avhandling var att undersöka portvaktskörtelkirurgins roll vid bröstcancerbehandling idag 
med fokus på kvarvarande begränsningar i olika kliniska situationer samt om resultaten från 
de olika ingående delarbetena kan ha inverkan på dess framtida indikationer. 
De specifka frågeställningarna var: 
1. Hur vanligt är det med spridning till portvaktskörtlarna vid förstadium till bröstcancer 
(DCIS), som innebär att tumörcellerna växer på plats i mjölkgångarna men inte har 
börjat infiltrera sin omgivning?  
2. I vilken omfattning ändras lymfavflödet från bröstet till armhålan efter en mindre 
diagnostisk bröstoperation? Går det att göra portvaktskörtelkirurgi i en andra seans? 
3. Kan portvaktskörtelkirurgi även användas för stadieindelning av kvinnor med 
bröstcancer som skall få cellgifter/kemoterapi före sin bröstoperation (neoadjuvant) 
och kan denna stadieindelning göras innan start av neoadjuvant behandling (NAST)? 
 58 
4. Kan portvaktskörtlekirurgi användas efter NAST för stadieindelning av kvinnor som 
hade konstaterad spridning till armhålan vid diagnos men där cellgifterna gjort att 
dessa metastaser i armhålan tillintetgjorts? 
 
Det första delarbetet (paper I) är en registerstudie där alla kvinnor opererade för ett 
förstadium till bröstcancer i Sverige mellan 2008-2009 analyserades med avseende på utfört 
kirurgiskt ingrepp i armhålan och eventuella tumörceller i dessa lymfkörtlar. Av 1273 
patienter hade portvaktskörtelkirurgi utförts i 753 fall varav fem hade metastas. Vi kunde inte 
påvisa några riskfaktorer för metastas i vårt material. Även eftersnittningar utfördes av 
tumörklossar från alla patienter med tumörceller i portvaktskörtlarna och ett dubbelt antal 
matchade kvinnor för att leta efter förbisedda millimetersmå områden där förstadiumet 
övergått till invasiv tumörväxt med förmåga att sprida sig i kroppen. Denna så kallade 
miktoinvasion påträffades i samma utsträckning i båda grupperna. 
 
I delarbete två (paper II) undersöktes lymfavflödet till armhålans lymfkörtlar hos 37 kvinnor 
planerade för ett mindre ensidigt bröstingrepp för en förmodat godartad förändring utan 
behov av portvaktskörtelkirurgi. Veckan före, respektive sex veckor efter operationen, 
genomgick kvinnorna SPECT/CT- undersökning på Karolinska Universitetssjukhuset i 
Huddinge. Denna undersökning innebär att ett radioaktivt spårämne sprutas, i detta fall i båda 
brösten, och att bildtagning sker med start efter en timme med en kombinerad gammakamera 
och datortomograf som tillsammanns genererar tredimensionella scintigrafiska bilder med 
tydliga anatomiska riktmärken. Vi kunde inte se någon statistiskt säkerställd skillnad i 
överensstämmelse i lymfdränaget efter kirurgin på opererade jämfört med icke opererade 
sidor eller i andelen procedurer där en radioaktiv lymfkörtel kunde upptäckas på opererade 
jämfört med icke opererade sidor. 
 
Delarbete tre och fyra (paper III och IV) baseras på en svensk multicenterstudie där 
tillförlitligheten och den kliniska nyttan med portvaktskörtelkirugi vid NAST utvärderades. 
På kliniskt lymkörtelfriska patienter utfördes portvaktskörtelkirurgi före start av NAST och 
lymfkörtelutrymning tillsammans med bröstkirurgi efter avslutad NAST, som nästan alltid 
utgjordes av cellgifter. 224 patienter analyserades i delarbete tre (paper III) och hos alla 
hittades en portvaktskörtel. Däremot var det nio kvinnor med frisk portvaktskörtel som trots 
detta hade sjuka lymfkörtlar i armhålan efter NAST, vilket ger en “falskt negativ kvot” på 7,4 
%. 
I delarbete fyra ingick 195 kvinnor som alla hade sjuka lymfkörtlar i armhålan innan NAST, 
konstaterat med finnålsbiopsi. Dessa kvinnor genomgick istället forsök till 
portvaktskörtelkirurgi efter avslutad NAST, tillsammans med bröstkirurgi och 
lymfkörtelutrymning. Hos 77,9 % påträffades minst en portvaktskörtel och i 14,1% var 
portvaktskörteln falskt negativ. Dock sjönk andelen falskt negativa till 4,0 % i de fall då två 
eller fler portvaktskörtlar hittades.  
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Sammanfattningsvis visar denna avhandling att kvinnor med förstadium till bröstcancer har 
en mycket låg risk för spridning till lymfkörtlarna och därför bör portvaktskörtelkirurgi 
enbart utföras i de fall man planerar att operar bort hela bröstet eller om det finns starka skäl 
att tro att tumören innehåller invasiva områden. Efter tidigare begränsad diagnostisk 
bröstkirurgi förefaller portvaktskörtelkirurgi tillförlitligt trots att lymfavflödet ändrar sig i viss 
utsträckning.Portvaktskörtelkirurgi utförd hos kvinnor före kemoterapi (NAST) är säkert. 
Hos kvinnor med konstaterad lymfkörtelspridning innan NAST bör axillutrymning utföras i 
de fall då endast en frisk portvaktskörtel hittas efter avslutad NAST. 
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